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ABSTRACT 
Ebola viruses (EBOV) cause severe disease symptoms in humans and in non-human 
primates in the form of viral hemorrhagic fever. Although EBOV outbreaks have not occurred 
in the U.S., the virus is of public health concern as a potential bioterrorism organism for which 
no vaccine or anti-viral is available. Fast-acting and prophylactic therapeutics are needed to 
reduce mortality due to outbreaks in other countries and for use in the U.S. if the virus is used 
in a bioterrorism attack. In view of the paucity of current antiviral therapies and diagnostic 
systems for EBOV, we provide an alternative solution by selection of high affinity 2’FY-
stabilized RNA aptamers that bind the EBOV surface exposed glycoprotein, GP1 and soluble 
glycoprotein (sGP). Aptamers are single stranded short nucleic acid oligonucleotides with 
sequences that enable high affinity and specificity for their targets. Aptamers have comparable 
affinity with antibodies, but they are not immunogenic and are raised by in-vitro methods. 
They can be selected to bind to a precise region of a protein. By this means, an aptamer binding 
the EBOV surface GP1 would prevent the interaction between the virus and the host cell, 
disrupt the viral life cycle and an aptamer against sGP can be integrated with a detection 
platform that can be used as a biosensor to detect Ebola infections.  
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CHAPTER 1 
INTRODUCTION 
Filovirus Overview  
Filoviridae family is composed of three genera: Ebolaviruses, Marburgviruses and 
Cueva viruses.  There are two species of Marburgvirus, Marburg virus (MARV) and Ravn 
virus (RAVV) and five species of Ebolavirus, Ebola virus (EBOV), Sudan virus (SUDV), Tai 
Forest virus (TAFV), Reston Virus (RESTV) and Bundibugyo virus (BDBV) [1]. Ebola virus 
is an enveloped, non-segmented and negatively stranded RNA virus with genome of roughly 
19kb. Ebola virus particle is filamentous in shape and genome encodes seven structural 
proteins beginning from the 3’ end: the nucleoprotein (NP), viral protein (VP35), VP40, the 
glycoprotein (GP), VP30, VP24 and the RNA dependent RNA polymerase (L). The viral RNA 
genome is encapsulated in NP that, along with VP35, VP30, and L form the replication 
complex [2] (Figure 1). VP 40 is the major matrix protein and is sufficient for budding of virus-
like particles (VLPs), VP24 is a minor matrix protein [3, 4]. In addition to these proteins, Ebola 
virus secretes into the blood stream soluble glycoprotein (sGP). It is a nonstructural, secretory 
glycoprotein, which shares a 295-amino acid sequence with the glycoprotein GP. Ebolavirus 
infection can cause hemorrhagic fever with mortality rates as high as 90% [5]. The most recent 
outbreak was in 2014  when the incidence and prevalence of Ebola infections exceeded any 
previous outbreak [6]. With its ability to cause severe pathogenicity and a high mortality rate, 
the potential of being used for bioterrorism and the absence of any licensed vaccines or 
therapeutics underscores the threat, this virus poses to public health [7]. 
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Filovirus Pathogenesis 
Filoviruses cause hemorrhagic fever in human and non-human primates and exhibit 
high rates of mortality reaching up to 90%. Initial infection occurs through direct transmission 
from bats which are believed to be the host reservoir [4]. Ebola virus enters the host through 
mucosal surfaces and breaks through the skin. Most human infections have been caused by 
direct contact with the human patients or cadavers or infected animal carriers. Infectious virus 
particles or viral RNA have been detected in the semen and genital secretions of infected 
patients [4]. The known infectivity titers in non-human primates have been reported to be  in 
the range of 107 to 108 plaque forming units/g[8], any exposure though the oral route can be 
associated with very high infectious doses. Transmission of the Ebola virus through an aerosol 
route has not been documented and is thought to be rare.  Ebola virus, once it gains entry into 
the body, targets a range of cells early during infection, including monocytes, macrophages 
and dendritic cells, and then spreads to a variety of other cell types, including epithelial cells 
in the visceral organs [10]. Transport of infected immune cells and free virus through the blood 
stream is believed to enable the virus to spread from the site of initial infection. The high 
lethality of Ebola viruses in large part is due to an early and strong inhibition of the innate 
immune response [20].  
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Ebola Virus Immune Evasion Strategies 
Phosphatidyl serine dependent 
Ebola virus particles are filamentous in shape and can be up to a micron in length, 
which would make it difficult for them to be taken in by the cells by clathrin or caveolin 
mediated endocytosis. Clathrin mediated endocytosis is usually limited to virions of 100nm 
whereas caveolin is around 50nm. It could be for this reason that Ebola virus is taken up by 
macropinocytosis. Phosphatidylserine is a lipid found on the outer leaflet of apoptotic cells 
where it alerts phagocytic cells to engulf the apoptotic cells by macropinocytosis. In a similar 
fashion, phosphatidylserine on the Ebola virus particles is recognized by the (T-cell 
immunoglobulin and mucin domain 1) TIM-1 receptors, interaction between TIM-1 receptor 
and phosphatidylserine mediates the entry of virus into the host cells. Ebola virus acquires 
phosphatidylserine from the plasma membrane microdomains, called lipid rafts, during the 
budding process. Lipid rafts are highly enriched for phosphatidylserine on the external 
leaflet[11].  The Ebola virus particles present themselves to phagocytic cells as apoptotic 
bodies and avoid initiating the inflammatory response by being engulfed by the cells.  [12, 13].   
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Preventing the interferon response 
VP35 
VP35 is a multifunctional protein, which is associated with the ribonuclear complex 
and links the viral RNA polymerase (L) to the nucleoprotein (NP) during viral replication. 
VP35 also inhibits α and β interferon responses by multiple mechanisms. One mechanism is 
mediated by inhibiting RIG-I and MDA-5, innate pattern recognition receptors that detect 
foreign cytoplasmic RNA. RIG-I recognizes 5’-triphoshophates of the blunt end of dsRNA and 
MDA-5 senses long dsRNA. RIG-I and MDA-5 associates with a common downstream 
adaptor IPS-1, which activates NF-kB, IRF-3, and IRF- 7 to trigger the expression of type I 
interferon and pro-inflammatory cytokines. VP35 is a decoy substrate for IKKε /TBK-1 
kinases and impedes the RIG-1 pathway by binding the N-terminal kinase domain of IKKε and 
prevents IRF-3 phosphorylation. Interactions of IKKε with other proteins such as IRF-1 and 
IPS-1 are also prevented due to binding of VP35 to IKKε [14]. These interactions successfully 
block the activation of genes with interferon responsive promoters [15, 16]. In a second 
mechanism, VP35 competes with RIG-I by binding to the blunt end of dsRNA, which prevents 
RIG-I and MDA-5 responses [17-19].  
VP24 
Typically, when innate immunity is functional, the host response to a virus infection is 
secretion of interferon proteins to generate antiviral responses in neighboring cells, signal 
hematopoietic cell responses and increase antigen presentation. Secreted interferon binds to 
type I and II interferon receptors, activating signaling via adaptor proteins, which results in the 
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phosphorylation and dimerization of the signal transducer and activator of transcription 
(STAT) proteins. These dimerized transcription factors are transported to the nucleus where 
they bind to interferon response elements and induce antiviral gene expression [20]. Since, 
these pathways are so important in fighting viral infections, viruses usually target them.  
Karyopherin-α1 is the nuclear membrane localized signal receptor that is responsible for 
nuclear accumulation of the STAT-1 dimers. VP24 interacts with karyopherin-α1 to inhibit the 
nuclear accumulation of STAT-1 and block interferon signaling. This mechanism prevents 
antiviral effects in cells expressing Ebola virus [21].  
RNA stability and replication 
The heterogeneous nuclear protein complexes, C1/C2 proteins ((hnRNP C1/C2), reside 
in the nucleus where they bind poly-U mRNA and assist in splicing before they are transported 
into the cytoplasm. They also engage in cap independent, IRES (Internal Ribosome Entry Site) 
dependent translation in the cytoplasm during mitosis [22]. Ebola VP24 causes relocalization 
of hnRNP C1/C2 from the nucleus to cytoplasm. It is hypothesized that C1/C2 might bind the 
poly-U tracts in Ebola viral RNA, thereby stabilizing it against degradation and enhancing 
genomic replication [22]. This suggests that Ebola virus uses the host machinery to prolong 
the half-life of its viral RNA and optimize transcription from its genome and viral replication.  
Filoviral Replication and Transcription 
Filovirus replication and transcription happens in the cytoplasm of the infected cell, the 
virus encodes its own RNA-dependent RNA polymerase that uses the negative-strand viral 
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RNA as a template for transcription and replication. Nucleocapsid assembly for the virus is 
mediated by three proteins NP, VP35 and VP30. The rate-limiting step for nucleocapsid 
formation is nucleoprotein (NP) assisted formation of helical bundle. [23]. This is followed by 
interactions with VP35 and VP30 and L to produce the ribonucleoprotein that encapsulates the 
viral genome. [24, 25]. For budding and formation of a virion, VP35 interacts with capsid 
protein VP40 and mediates the packaging of the nucleocapsid into the mature virion on the cell 
surface [26]. 
Replication of the RNA genome is initiated by the synthesis of positive sense 
intermediate (antigenome). The antigenome is the reverse complement of the RNA genome 
and it serves as a template for the generation of negative stranded RNA. Studies with Marburg 
and Ebola virus minigenome systems have established NP, VP35 and L as the minimal 
essential components for viral replication [27, 28] [29].  
Transcription process begins after the viral RNA is released into cytoplasm, the 
polymerase complex starts to transcribe it. Viral genome available for transcription is oriented 
in 3’ to 5’ direction, due to the polymerase complex stopping and reinitiating at each gene 
junction, transcription of the starting gene NP is favored. Due to sequential transcription, a 
gradient of transcribed gene products is generated. This leads to a non-homogenous 
distribution of viral proteins [30].  During transcription the viral RNA is polyadenylated as 
well as capped for cap-dependent translation of the viral mRNA [31].  
Little is known about the mechanism of switching from the transcription to the 
replication state but its hypothesized that the phosphorylation state of VP30 might play a 
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critical role in deciding if the polymerase complex will support replication or transcription 
[32].  
Viral assembly and budding are mediated by VP24 and VP40. To prepare the virus for 
budding VP24, one of the matrix proteins, associates with the RNP complex and functions as 
a signal to switch from the replication-transcription state to the viral assembly state [33].  These 
mechanisms ensure that the machinery for viral transcription and replication is tightly 
regulated.  
Ebola Virus Glycoprotein GP1, 2 
The fourth gene from the 3’ end of the filovirus genome encodes the viral envelope 
GP1, 2 (a glycoprotein). Viral glycoprotein (GP1) is a heterotrimer that forms spikes on the 
surface of the virus and is the only protein on the EBOV viral particle surface.  Folding and 
assembly of GP1 occurs independently of other viral proteins [34]. It is initially synthesized as 
a precursor that is later cleaved by furin, a proprotein convertase, into GP1 (140kD) and GP2 
(26kD) polypeptides that are linked by disulfide bonds [35]. The GP2 subunit contains two 
heptad repeat regions that facilitate assembly of GP into trimers, a transmembrane anchor 
sequence, and the fusion loop [34]. The heterotrimer (GP1 and GP2) assembles as a 450 KDa 
complex on the surface of the nascent virion [36]. The GP1 subunit contains the cell surface 
receptor binding site and a heavily glycosylated mucin domain. The residues responsible for 
mediating interactions between GP1 and the host cell are within the 230-residue N-terminal 
domain of GP1.  
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Deletion of the C-terminal mucin domain enhances viral infectivity in vitro [37-39]. 
This observation is explained by the crystal structure of EBOV GP (Figure2), in which the 
receptor binding site of GP1 is masked by a glycan cap created by the mucin domain [36]. The 
GP1 subunit responsible for interaction with the cell contains four different domains: base, 
head, glycan cap and mucin like domain (MLD). The first three domains of GP1 are important 
for expression and function of the prefusion state of the glycoprotein. The GP1 base forms a 
hydrophobic, semicircular surface that interacts with the internal fusion loop and heptad repeat 
of GP2, thereby acting as a clamp that holds the prefusion GP2 form. The head part of GP1 is 
believed to contain the receptor binding domain (RBD) with a significant portion of this 
domain exposed to the solvent. 
The structure of the GP2 subunit, which is responsible for the fusion of viral and host 
membrane, includes a hydrophobic internal fusion loop, two heptad repeats (HR1 and HR2) 
and a CX6CC disulfide bond motif, membrane proximal external region and a transmembrane 
anchor [40]. The internal fusion loop is wrapped around the outside of the GP trimer in the 
pre-fusion state, with its hydrophobic side chains sequestered from the solvent due to packing 
into a GP1 monomer.  
Although Ebola virus species are antigenically distinct, the GP1 RBD is highly 
conserved among them. The receptor binding domain of the Ebola viruses is masked by the 
highly glycosylated domains of the mainly N-glycosylated glycan cap and a mucin like 
domain, which is both N- and O-glycosylated [41]. Glycosyl groups protect proteins from 
degradation but can also obstruct interaction of the glycosylated protein with another molecule. 
Removal of the 7 glycan sites in the GP1 core had no significant effect on GP expression but 
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increased transduction compared with the wild type. Similar results were observed when the 
mucin domain lacked its N-glycosylation [41]. These results demonstrated that the N linked 
glycosyl groups on GP1 are not required for viral entry in Vero cells [41].  
Ebola Virus Glycoprotein (GP1,2) Interaction With The Host Cell 
Ebola viruses infect a broad range of cells and a host of proteins are known to enhance 
viral entry into the host cells including the C-type lectins L-SIGN, DC-SIGN and the tyrosine 
kinase receptor Axl [42-45]. Infectivity involves at least two recognition events 1) at the host 
cell surface that mediates endocytosis and 2) in the endosome to mediate cytoplasmic entry. 
The cell surface receptor for EBOV is believed to be the T-cell immunoglobulin and mucin 
domain 1 (TIM-1) receptor [46]. The usual function of the TIM-1 receptor is to bind to 
phosphatidyl serine (Ptd-Ser) on the surface of apoptotic cells and thereby facilitate 
phagocytosis of these cells [47]. It has been shown that TIM-1 facilitates the entry of Dengue 
Virus by directly interacting with the virion-associated phosphatidylserine [48]. 
Phosphatidylserine is the most highly represented anionic lipid in inner leaflet of plasma 
membrane, where it usually is around 15-20% of anionic lipids [49]. Ebola Virus also gains 
entry through interaction of the TIM-1 cell surface receptor and Ptd-Ser residue on the viral 
envelope. The TIM-1 receptor enhances the internalization of pseudovirions that do not express 
GP1, 2, confirming that TIM-1 and Ptd-Ser mediate the interaction for the viral entry into the 
cell. [50]. After its initial interaction with the cell surface receptor, the virus enters the 
endosomes through macropinocytosis. When the endosomes containing the virus particles 
mature to late endosomes, the viral GP is further processed and it then interacts with the 
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endosomal receptor. However, although TIM-1 and DCSIGN have been identified as cellular 
receptors for viral entry, the expression of TIM-1 and DCSIGN is not sufficient to make certain 
cells permeable to Ebola virus entry. This result suggests that there may be distinct mechanisms 
for Ebola mediated entry depending on which attachment factor is used for entry [51, 52]. 
Ebola virus requires endosomal processing before the final entry of the virus particle into the 
cell. The protease, cathepsin B initiates entry which cleaves off the mucin domain and glycan 
cap to expose the RBD [53-56].  
The endosomal receptor for EBOV is believed to be the Niemann-Pick C1 (NPC1), a 
lysosomal cholesterol transporter [57]. This conclusion is consistent with the observation that 
Npc1−/−  mice demonstrated significantly reduced viremia in comparison to wild type mice 
when tested in a mouse model of Ebola disease [58]. NPC1 is a 13-pass transmembrane protein 
found in the membranes of late endosomes and lysosomes of all cells [59]. It works together 
with another protein, NPC2, to mediate the transport of cholesterol between cellular 
compartments [60]. Binding site for C1 (NPC1) is exposed after the endosomal cysteine 
proteases cleave EBOV GP1 to remove the heavily glycosylated C-terminal sequences, which 
generates an entry intermediate comprised of the N terminal regions of GP1 and GP2 [54, 57]. 
The importance of the identified C1 (NPC1) binding site on GP1 was demonstrated with 
virions that contained mutations in the C1 receptor binding residues, which are vital for viral 
entry and for maintaining the conformation of the glycoprotein [57]. Recent studies have 
shown that TIM-1 and NPC1-mediated interaction is responsible for viral fusion in the late 
endosomes. Although, TIM-1 is primarily expressed on the cell surface, it is also found in early 
endosomes and can cycle between the endosome and the cell surface [61]. A monoclonal 
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antibody (MabM224/1) against the TIM-1 receptor inhibits the internalization of Ebola virus 
in Vero6 cells, which express the TIM-1 receptor. Thus, it is postulated that TIM-1 interacts 
with the Ptd-Ser on Ebola virus, is taken into the endosome, and along with the cleaved 
fragment of GP1, interacts with NPC-1 and initializes viral fusion with the late endosome lipid 
membrane [62]. 
GP2-Mediated Viral and Host Membrane Fusion  
The process of fusion of the viral and host cell membranes has a very high energy 
barrier. To lower the activation barrier, viral proteins must undergo huge conformational 
changes to generate sufficient released free energy.  The first step for viral-host cell membrane 
fusion in the endosome is to prime the envelope GP to a metastable conformation that can be 
subsequently used for viral fusion. The crystal structure of EBOV GP1,2Δmucin (mucin 
domain deleted) illustrates that the hydrophobic fusion residues are within the antiparallel β 
scaffold and the structure is not conformationally restricted [63]. The N terminal of the fusion 
loop has conformational freedom and is believed to aid fusion. In influenza and flaviviruses, 
the main trigger for fusion is low pH, which results in protonation of histidine residues located 
near positively charged residues in the prefusion state.  These protonated histidines are found 
in the post fusion conformation engaged in electrostatic interactions with the negatively 
charged residues [64, 65]. The trigger for Ebola virus fusion is not well defined. Although the 
low pH of the endosome is required for the cleavage of GP1,2 and for its subsequent interaction 
with NPC1, the change in pH due to endosome maturation is not involved in triggering fusion.  
However, it is unknown as yet if the cleavage of GP triggers the fusogenic conformation of the 
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virus [54] or the cleavage of GP by cathepsin B triggers another cellular factor that initiates 
the fusion [55]. Even though the fusogenic trigger is unknown, it is evident from the crystal 
structure that the GP2 hydrophobic patch, which clamps around GP1, must be released before 
fusion. Comparing the pre- and post-fusion conformations of GP1,2 and GP2 respectively, 
shows that the heptad repeat segments of GP2 unwinds from its prefusion state of  a ring around 
GP1, straightens and assembles into a 44 residue long helical rod like structure [63, 66, 67]. In 
response to the rotational and translational movement of heptad repeat, the internal fusion loop 
arranges itself to the top of the trimeric GP2 and adopts a 310 helical conformation, which is 
stabilized by membrane interaction with hydrophobic residues in the fusion loop that mediate 
penetration into the host membrane [68]. After formation of this intermediate conformation, 
GP2 folds on itself bringing the two heptad repeats HR1 and HR2 close together to form a six-
helix bundle. This collapse of the two GP2 heptad repeats brings the host and viral membranes 
closer causing the two bilayers to merge into a hemifusion stalk that eventually opens to a 
fusion pore. (Figure 3). 
Soluble Glycoprotein (sGP) 
GP gene in the Ebola virus genome produces three different sized proteins: full length 
676 aa GP1,2,  pre-sGP which is 364 aa in length and a 298 residue small secreted protein 
(ssGP) [69, 70].  These three proteins are produced because of transcriptional slippage of the 
GP gene. GP1, 2 and ssGP are produced when slippage of the viral polymerase occurs at seven 
consecutive uridines within the GP gene. With slippage of one U, an additional adenosine 
residue is incorporated into the mRNA, which results in two sequential open reading frames 
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becoming a continuous reading frame that encodes full length GP1,2. sGP is produced from 
the unedited version of the mRNA in which there is a stop codon at the end of the first reading 
frame. Slippage along two Us and incorporation of  two extra adenosines results in the 
synthesis of ssGP, a secreted homodimer [69, 71]. The ratio of transcripts of these three 
proteins have been shown to be (sGP:GP1.2:ssGP) of 71:24:5 in Vero E6 cells [71] suggesting 
that sGP is the main viral protein product of the GP gene. Although the time of release of sGP 
into the blood stream is unknown, sGP in 15 μL of serum, was readily detected by western blot 
in comparison to GP1,2, which could not be detected [72]. 
Soluble glycoprotein (sGP) is encoded by the GP gene in all species of Ebola Virus. It 
is initially synthesized as pre-GP which is shunted into the golgi complex via the signal 
recognition complex. The sGP precursor undergoes post translational cleavage at the C-
terminus to yield the mature form of the protein [73]. After its proteolytic cleavage it forms a 
103 KDa homodimer linked by two disulfide bonds at Cys 53 and Cys 306 [74, 75] with six 
N-glycosylation sites [75]. sGP  shares the first 295 amino acids with GP1, 2.   A recently 
determined cryo-EM structure of sGP showed that the monomeric structures of  GP1,2 and 
sGP are similar [Figure 4] [76].  Co-expression of sGP and GP2 by HEK293T cells resulted 
in an sGP:GP2 protein complex that was recognized by the known neutralizing antibody KZ52 
[77]. KZ52 is an antibody that was isolated from an Ebola survivor that binds to the interface 
of GP1 and GP2 [63]. Using Circular Dichroism, Fluorescence Spectroscopy and MALLS it 
was demonstrated that sGP, which is secreted as a disulfide linked homodimer, is mostly beta 
sheet with 15% alpha helix content, and is highly stable  at 37°C for up to 72 h [78]. 
14 
 
 
 
Role Of sGP In Ebola Pathogenesis 
sGP viral protein is secreted in large amounts by HEK293T cells and is present in the 
blood of infected individuals [77], due to its high concentrations in blood various studies were 
performed to determine its role in Ebola pathogenesis. One study suggested that sGP could 
inactivate neutrophils by the binding to CD16b, which is a neutrophil specific Fc receptor III 
[79]. However, these studies were challenged because the initial study overlooked the fact that 
sGP could bind the neutrophil receptor indirectly through the Fc region of anti-sGP antibody 
[80]. A later study confirmed that sGP immune complexes bound CD16b by demonstrating 
that sGP complexed with an Fab fragment binds to neutrophils [81] These results argued 
against the potential role of sGP as a neutrophil inactivator. 
Another potential role of sGP was to promote apoptosis of B and T cells during viral 
infection. Earlier reports had shown that lymphocyte apoptosis during Ebola infection could 
be mediated through Fas/FasL interactions [82].  But, later it was demonstrated that sGP alone 
or in combination with Fas ligands had no effect on frequency of Jurkat T cell death [82]. 
Investigators concluded that sGP does not induce apoptosis via extrinsic pathway.  Thus, the 
current evidence supports the conclusion that sGP is not involved in stimulating apoptosis of 
lymphocytes.  
A possible function of sGP in vascular dysregulation was also investigated, because 
the expression of cellular adhesion molecules had earlier been shown to increase in the 
presence of Ebola GP1,2. But, sGP and its degradation products failed to activate expression 
of adhesion molecules in endothelial cells or to alter the integrity of endothelial cell barrier 
[83]. Instead, when endothelial cells were treated with sGP and TNF-alpha (an inflammatory 
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signal that decreases endothelial barrier function), sGP restored barrier function, which 
suggested an anti-inflammatory role for sGP [83]. Further studies explored the relationship 
between the structure of sGP and its anti-inflammatory role. Mutations of Cys53Gly, 
Cys306Gly, and the double mutant failed to restore the barrier function.  Therefore, a fully 
functional sGP homodimer is required for the protein to restore barrier function [75]. Overall, 
these studies show that Ebola sGP might not have a role in the vascular deregulation but it 
might have an anti-inflammatory function.  
Immune modulation of host responses by sGP 
Antibodies in the sera of human Ebola hemorrhagic fever survivors cross reacted with 
sGP rather than GP1,2 [84]. Because sGP and GP1,2 are structurally similar they can be bound 
by antibodies that recognize shared epitopes. However, due to the higher rate of production of 
sGP in comparison to GP1,2, B cells that recognize sGP specific epitopes or shared epitopes 
outcompete the B cells that recognize GP1,2 specific antibodies. This is believed to be the 
reason for the biased population of antibodies that target sGP specific epitopes and GP1,2 
shared epitope. Thus, the presence of high concentrations of sGP in the blood directs antibody 
production towards sGP, which acts as a decoy to allow the viral infection to continue unabated 
[85]. 
Vaccine and Therapeutics For Ebola 
Until the 2014 Ebola outbreak no vaccines or therapeutics were available because the 
infected population was very small and few companies were interested in the market. However, 
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with the magnitude of the outbreak in 2014, various vaccine formulations were proposed and 
clinical trials were initiated. Clinical trials with rVSV-ZEBOV vaccine found that it was 70-
100% effective in providing protection therefore can be used in future outbreaks [86]. ChAd3-
ZEBOV, developed by GlaxoSmithkline in collaboration with the US national institute of 
allergy and infectious diseases is still in clinical trial. The Novavax recombinant Ebola vaccine 
is currently undergoing Phase II clinical trial.  Other products in development include an oral 
adenovirus (Vaxart), a different vesicular stomatitis virus candidate (Profectus Biosciences, 
recombinant protein (Protein Sciences), DNA vaccine (Invovia) and a recombinant rabies 
vaccine from (Jefferson University) [87].  
Apart from the vaccines, there are many candidate therapeutics being evaluated 
including small molecule inhibitors [88, 89] and siRNA based therapeutics [90]. ZMapp is a 
cocktail of humanized antibodies that target three different sites on the Ebola glycoprotein 
[91]. These three antibodies are produced by genetically modified tobacco plants and clinical 
trials for Zmapp were concluded in 2016 [92]. The drug was well received by patients; however 
it did not produce definitive results with the small number of patients in the trial. Therefore, 
the FDA allowed Mapp Biopharmaceuticals to make Zmapp available to a larger number of 
patients to obtain definitive answers.   
Diagnostic Kits for EBOLA  
WHO reported that, between 15th Feb 2015 and 19th April 2015, more than 26044  
people were infected and around 10808 died from Ebola Virus [93]. As just discussed, several 
potential drugs and vaccines are being tested, yet no FDA-approved treatment has yet been 
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commercialized. To minimize spread of the virus a means of early detection of Ebola virus is 
needed so that infected individuals can be quarantined. By 2014 WHO had received 17 
applications from diagnostic companies for devices to detect Ebola virus [94]. These included 
reverse transcriptase polymerase chain reaction (RT-PCR) methods for detecting genomic 
sequences, immunochromatographic strip formats and ELISAs. RT-PCR is the standard 
diagnostic method for Ebola virus and is highly sensitive. However, it requires trained 
personnel and specialized equipment in addition to high level biocontainment measures. In 
addition, RT-PCR involves several steps during PCR amplification and requires constant 
monitoring of the temperature. A constant power source is needed to limit the assay to specific 
laboratories. The WHO approved a gold strip procedure for detecting Ebola virus. It is less 
sensitive than RT-PCR and therefore would not detect an Ebola infection immediately after 
the symptoms appear. It also has a 15% false positive rate, which limits its application as a 
diagnostic kit. Current methods for Ebola detection dependent on the availability of necessary 
reagents, require close contact with infected samples, and a constant supply of power. This 
motivates interest in developing a robust, sensitive, and in-house diagnostic kit.  
Aptamers 
The term aptamer is derived from the latin word “aptus” which means “fit” and in 
Greek the word meros, which means “particles”. Aptamers are short oligonucleotides with 
sequences that enable them to bind to their selected targets with high affinity and specificity. 
Aptamers have access to a repertoire of tertiary structural elements, including bulges, loops, 
pseudoknots, and hairpin loops. Due to their varied structures and their capability to snugly 
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bind to the target molecule, the aptamer targets range from prokaryotic/eukaryotic cells, viral 
particles, small molecules, and proteins. The interactions between the aptamer and target 
consist mainly of a combination of stacking of aromatic rings, electrostatic and van der Waals 
interactions and hydrogen bonding [95, 96]. 
SELEX (Systematic Evolution of Ligands through Exponential enrichment) is a 
process that involves progressive siphoning of oligonucleotides (aptamers) through iterative 
rounds of partitioning and amplification [97]. A randomized pool of RNA or ssDNA is 
incubated with target molecules under specific buffer conditions. Oligonucleotides that bind 
the target are separated from the unbound and are later amplified. The process is repeated until 
the pool randomness is significantly reduced [96 168]. 
SELEX   
Library Generation  
The first step in SELEX process is to generate a randomized sequence oligonucleotide 
library, which consists of ssDNA oligonucleotides comprised of a 20-60 nt random region 
flanked by constant primer regions to be used for amplification. For selection of DNA aptamers 
the synthesized pool can be directly used. Whereas for RNA aptamer selection, ssDNA pool 
is converted to dsDNA and modified to include a T7RNA polymerase promoter using a primer. 
The maximum number of random sequences in the library can be determined using 4n with n 
being the number of positions in the random sequence. For our SELEX experiments we used 
53 nucleotides in the random regions which translates to ~1032 possible sequences. However, 
our starting pool size includes only 1015 oligonucleotides. It has been reported that the 
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probability of an aptamer for its target ranges from 10-13 to 10-14 with mean/mode probability 
of 10-11 [98]. Therefore, a pool of 1015 complexity is frequently used for aptamer selection.  
Things that need to be considered in the pool design are pool length, which will determine the 
complexity of the pool, and nucleotide composition of the random sequences and constant 
regions. Long oligonucleotides can be expected to adopt multiple secondary structures, which 
might impede the correct folding of the desired binding motif. From studies to determine the 
optimal length of the random region in oligonucleotide libraries it was suggested that longer 
random pools (70-200nts) should be used to select for ribozymes, whereas shorter 
oligonucleotides (<70nt) would serve the purpose for selecting aptamers [99]. Experiments 
with pools containing different lengths of random region (16, 22, 26 50, 70 and 90) were used 
to select for an aptamer that binds isoleucine, results showed that the optimum pool length for 
isolating the desired aptamer was 50-70 nt [100]. A second important factor in designing pools 
is the complexity of the pool. This depends on the ratio of the four nucleotides used to create 
the ssDNA library, which can be determined in the manufacturing process [101, 102].  
Chemically modified nucleotides can be used to introduce new features to aptamers 
such as enhancing the sites of interaction with the target, improving the aptamer’s structural 
stability or providing enhanced nuclease resistance [103, 104]. Two approaches can be used to 
generate modified nucleotides. The first is to incorporate modified nucleotides at the time of 
pool generation. However, this approach could be a problem if DNA or RNA polymerase will 
not recognize the desired modified nucleotide as substrate. A second option is to modify the 
already selected aptamer. However, a modification to an already selected aptamer might alter 
the binding affinity or completely abolish binding [102].  
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Different techniques have been utilized to obtain modified aptamers conforming to a 
desired function. For example, 2’F and 2’NH2 modifications in the 2’ ribose have been 
included to improve the aptamer structural stability and nuclease resistance [105, 106].  
Nucleotides containing photoactivable functional groups (e.g. 5 iodo,5-bromo and 4 
thiouridine), which can covalently crosslink with a target protein, have also been used to 
increase the affinity and specificity of the aptamers for their targets [107]. Modified aptamers 
containing fluorescent groups have been used to study the binding of the aptamer to the protein 
[108]. Amino acid side chain, like groups on 5-benzylaminocarbonyl-dU, 5-
napthylmethylaminocarbonyl-dU, 5-tryptaminocarbonyl-dU and 5-isobutylaminocarbonyl-
dU, confer a significant increase in chemical diversity, thereby increasing the chances of 
interaction with proteins.  For example, SOMAmers  (Slow off rate modified aptamers) are 
ssDNA aptamers with modified uracils and 5-methyl-dC [109]. 
Another important aspect of pool design is the design of constant regions. The sequence 
of the constant region affects the amplification efficiency during PCR and RT (reverse 
transcription) in case of RNA. The constant regions should be designed so as to not form stable 
secondary structures [100]. Primers corresponding to the constant regions should also not form 
strong secondary structures or include sequences that can cause primer dimers to form. To 
improve amplification efficiency, the 3’ primer end should have WSS (W=T or A and S= G or 
C) because polymerases can extend well with ACC at the 3’ end.  A/T rich regions at the 3’ 
end can be used to avoid mispriming [110]. 
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The selection process  
SELEX process (Figure 5) starts with the incubation of the target with a pool of 
oligonucleotides with random central sequences followed by a selection step in which the 
bound oligonucleotide is separated from the unbound using a partitioning method. After this 
separation for an RNA aptamer the selected RNA is reverse transcribed and further amplified 
through PCR. In case of selection for a DNA aptamer the bound ssDNA is PCR-amplified. 
Multiple rounds are performed in succession, which involve in vitro transcription for RNA 
aptamer selection and separation of single stranded DNA for DNA aptamers. After multiple 
rounds have been completed, the pools are analyzed by Next Gen Sequencing or Sanger 
sequencing and evaluated for their ability to bind to the target with high affinity and specificity.  
Aptamer Selection Methods 
Filter capture 
The filter capture method has been used extensively for selection of aptamers. The 
principle factor in the method is the nonspecific binding of the target protein to the 
nitrocellulose filter with the oligonucleotides passing through. Oligonucleotides bound to the 
protein are trapped on the filter. This method has been widely successful but has the following 
limitations 1) the efficiency of protein capture varies with the protein, 2) small molecules 
cannot be captured on the membrane, and  3) certain aptamers bind to nitrocellulose 
membranes in the absence of their protein target [111]. The filter capture method relies on the 
true equilibrium binding of aptamers to the target protein in solution in comparison to other 
methods in which either the target or the aptamer is immobilized on a solid support [112]. In 
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all these methods, including the filter capture method, the washing steps that follow the 
partitioning can distort the equilibrium achieved in binding if the complex is characterized by 
a high off-rate. However, the washing step is the shortest in the filter capture method compared 
to others and thus least likely to influence the outcome. The filter capture method is also widely 
used for evaluating the binding of the selected aptamers to the target protein [113]. 
Bead based SELEX 
Immobilization of target molecules on a solid support is another method for selection 
[114], various affinity tags (6X his, GST and MBP) can be used, in addition to coupling 
chemistries such (amine, thiol or carboxyl). In bead based selection, target molecules can either 
be pre-immobilized then incubated with the target library or the molecules can be incubated 
with the target library and then captured by the affinity column. Various versions of affinity 
chromatography have been used for selections such as 1) MEDUSA (Microplate based 
enrichment device used for the selection of aptamers) [115], 2) the particle display method 
[116] in which emulsion PCR is used to immobilize 105 copies of a single clonally amplified 
ssDNA aptamer on each bead, the beads then incubated with fluorescent labeled target 
molecules and sorted by flow cytometry, and 3) MonoLEX, which has been shown to generate 
ssDNA aptamers in a single round that bind whole vaccinia virus particles [117].The 
limitations of Bead-based SELEX are the restrictive interaction surface, requirement for 
electronic instruments and flow pumps and increased non-specific interactions due to density-
dependent cooperative target binding [118]. 
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Electrophoretic SELEX 
EMSA (Electrophoretic Mobility shift assay) has long been used for downstream 
applications during SELEX, mostly for evaluating the binding of potential aptamers to the 
target protein.  However, this method has also been used for aptamer selection [119]. Although 
this method offers advantages such as equilibrium binding and separation of the bound and 
unbound populations, it can be used with only some proteins and under limited buffer 
conditions. As well, the volumes that can be accommodated in the gels used for separation are 
too small to include the number of oligonucleotides required for the maximum possible 
sequence diversity for SELEX. Therefore, it is wiser to use this method for downstream 
applications.  
A modification of EMSA is capillary electrophoresis which also relies on the 
electrophoretic mobility of the aptamer, but separation is in the capillary as opposed to the gel 
[120]. However, this method is limited to molecules that are within a certain size bracket and 
that are charged so they can be resolved on the capillary.  
Microfluidic SELEX 
In the recent times, microfluidic SELEX has been used for selection of aptamers. There 
are two different kinds of platforms 1) the target molecule is immobilized on micromagnetic 
beads [121] and 2) the target molecule is encapsulated in sol-gel, gel like porous silica material 
[122]. Microfluidic platforms allow fewer rounds of selection due to reduction in the available 
target molecule along with function to perform continuous washing. This continuous washing 
step allows removal of weak and nonspecific binders [123]. Since they are small, the use of 
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reagents is considerably reduced for microfluidic methods and the sol-gel based microfluidic 
system can be utilized to select against multiple targets in one experiment.  Even though the 
advantages of this method are many, the usage of this method might be limited due to the 
requirement for fabricated devices and electronic instruments. In sol gel based platform there 
is also the chance of undesired effects of a chemical reaction during sol-gel formation on the 
target molecule.  
Cell SELEX 
Cell-SELEX is used to select for aptamers against cells or cell fragments rather than 
targeting a specific protein.  In all SELEX procedures, negative selection against proteins or 
cells other than the desired biomarker helps in gaining specificity towards the targeted 
biomarker. Cell SELEX has been used to identify aptamers that can differentiate between 
normal or diseased cell types [124, 125] and therefore the negative selective steps are generally 
against normal cells. Cell SELEX has been used to select aptamers with therapeutic potential. 
In terms of experiments, positive and negative selections can be done under conditions of 
steady state equilibrium binding. Due to the possibility of nucleic acid aptamers being either 
degraded or internalized during selection, Cell-SELEX protocols usually employ shorter 
incubation periods than necessary for reaching equilibrium. Since cell surfaces also display 
non-target cellular proteins, it is difficult to achieve very high specificity towards the target 
molecules. TECS SELEX addresses this problem by overexpressing the desired target protein 
for selections. An aptamer that recognizes the TGF-β type III receptor with nanomolar affinity 
was successfully selected using this method [126]. Another complication of Cell-SELEX is 
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that it is prone to artifacts resulting from the presence of dead cells in the selection population 
Cell-SELEX protocols use FACS to separate bound and unbound aptamers [127]. This enables 
sorting of live and dead cells along with selecting cells with bound aptamers [128].  
High Throughput Sequencing and Data Analysis 
Incorporation of high throughput sequencing into the SELEX protocol for the analysis 
of enriched aptamer libraries and identification of candidate aptamers has been the most 
informative recent change in SELEX applications. Previously, enriched aptamer pools were 
cloned into a plasmid and a few hundred individual clones were sequenced to identify high 
affinity aptamers. In contrast, high throughput sequencing analysis has a readout of over a 
hundred million sequences. Candidate aptamers can be selected at much earlier rounds by 
studying the enrichment of an oligonucleotide with a particular sequence across various 
rounds, whereas conventional cloning-based aptamer identification required multiple rounds 
until an ensured enriched population was observed [129]. Illumina platforms are a preferred 
platform for NGS as they offer a significantly higher number of sequence reads with read 
lengths, which would cover the random regions and also the constant regions of most libraries 
[130, 131]. A large number of reads helps in gaining a more comprehensive insight into the 
sequence and structural features of the aptamers selected and a broad perspective on the 
progress of each SELEX process.  Information gathered through NGS  has also helped to 
predict secondary structure of the RNA aptamer and to identify appropriate truncations that 
yielded a better binding aptamer [132]. Given the ability of NGS to sequence multiple SELEX 
rounds simultaneously, it can be used to monitor the selection process as it proceeds. For 
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example, in a recent study SELEX pools derived from a genomic library selected against the 
E.coli Hfq protein were run in parallel with a control SELEX (Neutral SELEX) that did not 
include the target during the selection steps and was subjected to the same PCR and RT 
treatments.  The analysis of various rounds revealed that selection with the target progressed 
independently of the Neutral SELEX, with the former resulting in substantial enrichment of 
certain sequences whereas with the latter there was no enrichment of sequences [133].  
It is widely accepted now that even highly enriched libraries contain many thousands 
of potential aptamer sequences, many of them present in the populations in lower numbers. It 
has also become more evident that the most abundant oligonucleotides obtained in the final 
SELEX pools might not have the sequences for the highest target affinities. Other than 
selection for affinity to the target, reasons for high abundance of an oligonucleotide with a 
sequence in a selected pool could be PCR amplification bias or affinity of the oligonucleotide 
with that sequence to the partitioning matrix. Therefore, the fold enrichment over one or more 
SELEX rounds rather than abundance is a much better determinant of high affinity aptamers 
[131]. Tracking fold-enrichment is a good way to identify aptamers especially if the starting 
library is biased.  
The current capability of generating an immense amount of data and its contribution to 
better understanding the SELEX process has resulted in high throughput sequencing being 
used by most aptamer research groups to analyze the SELEX results. Despite its popularity, 
the development of specific bioinformatics tools for identification of candidate aptamers from 
the huge amounts of sequencing data is limited. Current bioinformatics tools based on 
clustering identify top clusters and the aptamer population can be traced to identify the 
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enriched sequences. Current tools also allow sorting of the putative aptamer sequences via their 
sequence structure motifs [134-136]. However, bioinformatics tools are still needed that better 
predict the target binding aptamer candidates based on structure or sequence classifications.  
 Aptamers vs. Antibodies and The Current State Of The Market 
Antibodies, have been widely used for various purposes. Apart from being used in the 
lab for research, they are used as therapeutics drugs, are also functionalized on biosensors for 
detection purposes. Although, antibodies have been fundamental to several applications, there 
are limitations associated with its usability. Synthesis of an antibody is time consuming and 
there is always an issue of reproducibility between batches. Neutralizing antibodies have been 
traditionally used to prevent the spread of viral infections. But, no neutralizing antibodies have 
yet been commercialized for EBOV. Also, antibodies used in passive immunity must be 
“humanized” to prevent their immunogenicity.  Thus, even if there were an effective anti-
EBOV antibody available, it would be very expensive and time consuming to humanize the 
antibody. Antibodies due to their short shelf life, require proper storage conditions, therefore 
when used for a detection platform, conditions amenable for preserving antibodies is needed. 
In addition, to perform techniques like RT-PCR or ELISAs trained personnel is required. 
Usage of antibodies adds up to additional costs and require infrastructure, regions affected by 
Ebola viruses have poor infrastructure therefore storage of these drugs and kits require 
additional costs and efforts.  
Aptamers have been established as a potent alternative for antibodies. Aptamers have 
been selected against several targets to function either as a therapeutic drug or as a biosensor. 
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Aptamers have notable advantages over antibodies that include non-immunogenicity, in-vitro 
production, and stability. Aptamers can be rapidly reconstituted and the in vivo 
pharmacokinetics and tissue distribution can be tuned by chemical modifications including 
conjugation to high molecular weight molecules such as PEG. Conjugation can increase the 
half-life of an aptamer from 40 min to 50 h. Modifications such as with fluorine in the 2’ 
position also increase stability in serum [137].  
Even though aptamers were discovered in 1990 they still haven’t effectively transcended from 
research labs into the market full-fledged even though they hold many advantages over 
antibodies (Table 1). Only one aptamer-based product Macugen has cleared clinical trials and 
is available in the market. The huge investment of pharmaceutical companies in the antibody 
market may be partly responsible for the resistance against aptamers. Even though few 
aptamers are in the market, the research on aptamers hasn’t receded.  A handful of companies 
have been developing and marketing aptamers as antibody-like binding reagents for research 
and development. These companies are Soma Logic (Boulder, CO, USA), OTC Biotech (San 
Antonio, TX, USA), Aptagen (Jacobus, PA, USA), Base Pair Biotechnologies (Houston, TX, 
USA), NeoVentures Biotechnologies (London, ON, Canada), Aptamer Sciences (Pohang, 
Korea). A few companies marketed aptamers as components of assay kits or concentrating 
devices, such as NeoVentures Ochratoxin A. Soma Logic , a company at the forefront of 
aptamer research, has been pushing its technology, SOMAmers and SOMAscan aptamer 
platform sensors, in the diagnostic market [138]. 
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Aptamers In The Diagnosis Of Viral Infections 
Proper diagnosis of any viral infection is important for preventing its spread. Symptoms 
of an acute infection are at first non-diagnostic and associated with a variety of viral infections. 
To prevent its spread, it is imperative that the infectious agent be identified in the early stages.  
Aptamer development to date has been concentrated mostly on the well-known viral diseases 
such as HIV, Influenza virus, SARS and HPV [155-158]. Little research has been done on a 
wider variety of other viral diseases, including Ebola virus. Very few aptamers have been 
reported that bind Ebola viral proteins or are directed towards blocking an antiviral function 
[159, 160].  
There is a wide range of aptasensor options designed based on different principles for 
detection of viral particles. An aptasensor was  designed to detect avian influenza virus, based 
on the principle of quartz crystal microbalance [161]. Gold microelectrodes with impedimetric 
Table 1: Advantages of aptamers 
 
Advantages References 
Bind to a wide range of targets including 
metal ions, metabolites, proteins, viruses & 
mammalian cells 
[139-144] 
Aptamers can be synthesized chemically, 
reducing batch to batch variation and can be 
used as tools for drug loading and antidote 
application. 
[145] 
Aptamers generate little to no 
immunogenicity in therapeutic applications. 
[140, 146-148] 
Aptamers can be conjugated to molecules 
such as drugs, carriers, toxins and siRNA for 
therapeutic applications. 
[148-151] 
Aptamers can be conjugated with imaging 
probes for molecular imaging applications 
[152-154] 
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properties allows one to distinguish between active and inactive forms of virus.  Using specific 
DNA aptamers viable virus was detected by using the impedimetric sensor [162]. Other 
approaches to detect viral antigens include an RNA aptamer sensor to the HCV core antigen 
in which fluorescent dye ( Cy3) conjugated RNA aptamer  was the means of detection.[163]  
In another study an aptamer to viral glycoprotein E2 was selected using CS SELEX and 
demonstrated to inhibit HCV infection in Huh7.5.1 cells [144]. 
Comparison of aptamer based tests with other analytical methods 
Most current methods to detect virus infections rely on Enzyme linked immunosorbent 
assay (ELISA) or RT-PCR [161, 164, 165]. However, ELISA is reported to have low 
sensitivity and very high rates of false positives [166-168]. It also cannot be broadly applied 
because of the need for specific antibodies that are difficult to obtain for several viral diseases 
[169]. RT-PCR can be performed without application of antibodies and can detect the viral 
genome efficiently. It is also a sensitive method. Although the advantages are many for RT-
PCR, it requires expensive enzymes and trained personnel to do these analyses.  
Aptamers could be used to circumvent bottlenecks in the current detection systems for 
viral diseases. Properly developed and authenticated aptamers could efficiently differentiate 
between infected and non-infected cells.  
On a Hydrogel coated QCM (Quartz crystal microbalance aptasensor) biosensor, anti-
H5 antibodies were coated in parallel with anti-H5 aptamers. Although, same concentration of 
antibody was coated as the aptamer, the detection limit of H5N1 with anti-H5 antibody was 
0.128U whereas with the aptamer the detection limit was 0.0128U. [161, 167]. In addition to 
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providing higher sensitivity, detection using aptamers takes less time than with antibodies or 
PCR. For example, to detect avian influenza virus the time for detection by ELISA or qPCR 
would be 3 hours and 5 hours respectively, whereas with an aptasensor it only takes 1.5 hours 
[165-168]. 
Aptamers In Preventing The Fusion Of Virus Particle To The Host Cell 
Apart from diagnosis, another obvious function of an aptamer could be as a therapeutic. 
An aptamer could act as a therapeutic agent by preventing the interaction between the viral 
proteins and the host cell receptor proteins. Many aptamers have been selected that inhibit viral 
entry. An RNA aptamer (B40) that binds HIV gp120 inhibits viral interaction with T cell co-
receptor CCR5. Application of the aptamer resulted in a decreased concentration of p24 
antigen in the supernatants from virus-infected cultures of human peripheral mononuclear 
blood cells as measured by ELISA. Further characterization of the aptamer showed that it binds 
to the core conserved region of gp120 [170-172].  
 E2 protein is a potential target for creating blocking aptamers against HCV infection. 
E2 is a coreceptor of human CD81, which is presented on hepatocytes and B lymphocytes. 
ZE2, a DNA aptamer selected against, E2 blocked E2 binding of a wide range of HCV 
serotypes to Huh7.5.1, human established cells line of hepatocellular carcinoma cells. The 
presence of the aptamer reduced viral RNA levels was tested by qPCR. [144]. 
A DNA aptamer A22 to the influenza virus HA protein, blocked influenza virus entry 
into MDCK (Madin-Darby Canine Kidney).  Cell viability increased in proportion to A22 
aptamer concentrations from 50 to 100 pM. The therapeutic potential of this aptamer was also 
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demonstrated in an animal model in which mice infected with A/Texas/1/7 influenza strain and 
simultaneously treated with the aptamer A22, lost weight slower that the non-treated control 
group [173]. C7-35M, a DNA aptamer that binds to receptor binding region of hemagglutinin 
binds to the virus particles and inhibits the binding of the virus to the host cell receptors. [174]. 
Similar studies tested the effect of aptamers against human cytomegalovirus infections. 
Two RNA aptamers that recognize HCMV viral glycoproteins B and H, reduced the infectivity 
of cytomegalovirus in a human foreskin fibroblast cell line culture [175]. Aptamers against 
HSV-1 bound viral glycoprotein D, a ligand of Nectin-1, which mediates HSV entry into the 
host cell. Reduced infectious potential of HSV-1 was observed in proportion to the dose of this 
aptamer. The treatments showed no evidence of cytotoxicity and the aptamer could distinguish 
between HSV-1 and HSV-2 strains [176].  
In my thesis, data from SELEX experiments to select 2’Fluoro pyrimidine modified 
RNA aptamers against Ebola glycoproteins GP1,2 and sGP is presented.  
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Figure 1:  Ebola Virus Particle.  
Filamentous Ebola virus particle, Nucleocapsid comprises of RNA polymerase (L), 
Nucleoprotein (NP), VP35, VP30. Major and minor matrix proteins laying beneath the viral 
membrane VP40 and VP24. Anchored glycoprotein (GP) on the surface of the virus particles.  
Reprinted by permission from [177]. 
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Figure 2: X ray crystallography determined structure of GP1,2 ΔmucinΔtm. 
 
The structure of Ebola virus glycoprotein bound to neutralizing antibody KZ52. GP1,2 is a 
heterotrimer expressed on the surface of the viral membrane. The cartoon depicts the mucin 
domain that shrouds the protein along with glycan cap. The red region is supposed to be the 
receptor binding domain. Reprinted by permission from [63]. 
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Figure 3: Prefusion and and postfusion conformational switch of GP1,2 glycoprotein. 
 
The cartoon depicts the interaction of GP1,2 with host cell receptors followed by 
internalization via micropinocytosis. Once the virus is internalized into the endosomes, low 
pH dependent proteases cleave the glycan cap and mucin domain to expose the receptor 
binding domain 19-KDa core bonded to GP2. The receptor binding domain interacts with a 
receptor in the endosomes and this interaction allows a conformational change within GP2. 
This conformational change allows GP2 to release its internal fusion loop (IFL) and insert into 
host cell membrane. Interaction between the heptad repeats 2 and 1 brings host cell and viral 
membrane into contact and forms a hemifusion stalk. The hemifusion stalk causes the 
formation of a fusion pore. Reprinted by permission from [36]. 
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Figure 4: CryoEM determined structures of full length GP1,2 glycoprotein and soluble 
glycoprotein (sGP). Cryo EM determined quaternary structure of GP1,2. The figure also 
depicts the residues of N linked glycosylation and mucin domain sites.Cryo EM determined 
structure of sGP shows a parallel homodimer connected by disulfide bonds at the N and C 
terminus. The monomer structures of GP1,2 and sGP are similar. Reprinted by permission 
from [76] 
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Figure 5: SELEX protocol for the selection of RNA aptamer that binds the target protein. 
 
A DNA pool with a complexity of 1015 was PCR amplified, followed by transcription to 
prepare an RNA pool. The RNA pool was incubated with target protein and non-binders were 
separated by capture on a nitrocellulose filter. Retained RNA was eluted and reverse 
transcribed followed by PCR to amplify the selected sequences. This process was performed 
for 8-10 times before submitting for NGS.   
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ABSTRACT 
Nucleic acid aptamers have advantages over antibodies for incorporation into sensing 
devices. These advantages include stability to storage in the dehydrated state, structural 
stability for repetitive use, and compatibility with many sensing/transducing mechanisms. 
Such capability is important for detecting Ebola virus (EBOV) for which epidemics frequently 
start in locations that lack sophisticated equipment. sGP (soluble glycoprotein), a nonstructural 
Ebola viral glycoprotein, is an EBOV biomarker that is secreted in abundance in the blood 
stream even during the early stages of infection. Here, we report the selection of 39SGP1A, a 
2’flouro pyrimidine (2’FY)-modified RNA aptamer that specifically binds to sGP and does not 
bind human serum albumin, the most abundant protein in human blood. We demonstrate by 
computational and biochemical analysis that the recognition motif of 39SGP1A is a novel 
polypyrimidine-rich sequence. The replacement of the F group in the 2’ position of the ribose 
with an OH group resulted in complete loss of affinity for sGP. Computational structural 
modeling suggests that this motif could form a compact surface for protein interaction for 
which modification by fluorine increases molecular hydrophobicity.  
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INTRODUCTION 
Ebola virus, in the family of Filoviridae, is a highly virulent enveloped RNA virus that 
causes hemorrhagic fever with 50-90% fatality and for which early detection is the key to 
controlling epidemics such as have occurred in the recent past.  The Ebola virus GP gene 
encodes two glycoproteins with the surface exposed trimeric glycoprotein (GP1,2) being the 
minor product. The major translated product is sGP (soluble glycoprotein), which is conserved 
amongst the five Ebola virus species (1,2).  sGP shares its first 295 amino acids with GP1,2 
but has a unique 28 amino acid carboxy terminus. Monomers are disulphide linked (at C53 and 
C306) in a parallel orientation and appear in the blood as homodimers. It is N glycosylated at 
6 positions and C-mannosylated at W288. Due to their sequence homology sGP and GP1,2 
have similar monomeric structures (3).  Although, the role of sGP in pathogenesis is not yet 
established, antibodies elicited during infection cross react with sGP and GP1,2. This 
observation supports role for sGP as a decoy for antibodies against GP1,2 on the virus particle 
(4). Consistent with this hypothesis is the observation that sGP is secreted in abundance in the 
early stages of infection. Thus, it is an excellent choice as an Ebola virus biomarker. 
Despite its clear advantage as a biomarker for Ebola virus infections, sGP has been so 
far overlooked for this purpose. Here we describe the application of SELEX (5-7) combined 
with Next Gen Sequencing (NGS) and analysis by APTAGUI to select a 2’FY-RNA aptamer 
(39SGP1A) with high affinity and specificity for sGP. Aptamer 39SGP1A binds sGP tightly 
with a Kd of 27nM. By contrast, 39SGP1A does not bind human serum albumin. The 
requirement for structure in the binding of 39SGP1A to sGP is evident by the lack of affinity 
for sGP of the RNA (2’OH) version of this aptamer, which distinguishes the 39SGP1A motif 
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from the RNA recognition domain of the polypyrimidine tract binding protein (8-10). 2’F 
modification, which provides resistance against endonucleases (11) also results in 
conformational differences from the 2’OH RNA. The 2’F-modified ribose sugar tends to adopt 
the C3’ endo conformation and stabilizes the RNA structure (12). In addition, the inclusion of 
fluorine modifications increases molecular hydrophobicity. Here, we describe the aptamer and 
characterize its interaction with sGP, identifying a novel 2’FY-RNA binding domain as a poly-
2’F-U loop with GAGC in the stem.  
RESULTS 
Selection of 2’FY-RNAs with High Affinity for sGP 
2’FY-RNAs with high affinity for sGP were selected by SELEX from an 
oligonucleotide pool, consisting of a 53nt random region sequence flanked by 25 bases 5’ and 
3’ constant regions with a starting complexity of 1015 molecules of RNA. The protocol 
followed a mathematically defined approach of starting with a relatively high molar ratio of 
2:1 (RNA: sGP) followed by harmonic reductions in the sGP concentration (13) to increase 
the stringency of selections (Fig.1B). To eliminate non-specific sequences binding to the 
nitrocellulose membrane, negative selections were performed at rounds 2 and 4.  After 9 rounds 
of selection, enrichment of the pools was analyzed by nitrocellulose filter capture assay and 
EMSA. The binding curve of the initial pool did not reach saturation, whereas the binding 
curve of the final pool was biphasic with saturation achieved at ~100 nM and ~1uM 
respectively suggesting selection of high and low affinity RNA binders (data not shown). The 
filter binding results were corroborated by the results from electrophoretic mobility shift assay 
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(EMSA) results using the pools from the 1st and 9th rounds RNA pools.  The 1st, 4th, 6th and 9th 
rounds pools were given for Next Gen Sequencing Analysis and simultaneously 9th round pool 
was sub-cloned and sequenced by TOPO-TA cloning.  
Sequencing Analysis and Identification of Conserved Sequence Motifs 
APTA GUI (14), an open source graphical user interface was used for the Next Gen 
Sequencing data analysis. APTAGUI provides essential information regarding the quality of 
the data by separating the reads into several rounds and extracting randomized sequences. 
APTA GUI also generates enrichment ratios across the selection cycles, which helps in 
selecting prospective sequences for further analysis.  In addition to individual sequences it also 
provides information about various aptamer clusters and sequence families. The APTAGUI 
platform allows the user to study the mutation count on each individual sequence. Due to its 
extensive analysis of the aptamer families, it greatly facilitates the identification of aptamers.  
Next Gen Sequencing Analysis (Figs. 1A, C, D). The top 10 Sequence clusters obtained by 
TOPO TA cloning were identical to the Top 10 clusters obtained from Next Gen Sequencing 
analysis. 
Analysis of the sequences in the top 10 clusters from NGS with MEME (15) identified 
a conserved sequence motif of a stretch of U’s and GAGC (Fig. 1E).  No other sequence 
structure motifs were found in other enriched clusters. In all the secondary structures predicted 
for the sequence motif by MFold (16) the poly 2’F-U’s were in a loop followed by GAGC in 
a stem. 
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The poly2’F-U-GAGC Sequence Motif Identifies A High Affinity Aptamer 
The affinities of 2’FY-RNA oligonucleotides 5183, 5177, 5179 and 5182 containing 
the poly 2’F-U-GAGC sequence motif were compared with oligonucleotides 4789, 5181 from 
the top sequence cluster that did not contain the motif. In the initial titrations, we observed 
saturation at 100nM for all sequences containing U rich motif suggesting high affinity binding. 
The results, demonstrated for 2’FY-RNA-5183 and 2’FY-RNA-4789 revealed high affinities 
(Kd = 20-50 nM) for oligonucleotides containing the poly 2’F-U-GAGC sequence motif and 
low affinities (Kd = 0.5 to 1uM) for sequences that did not contain the motif (Fig. 2 A-D). That 
the 2’FY modification is essential for 2’FY-RNA-5183 binding to sGP is demonstrated by the 
observation that the same sequence in the form of an RNA (with 2’OH) did not bind sGP (Fig. 
2A). sGP binding by 2’FY-RNA 5183 was confirmed by electrophoretic mobility shift assay 
(EMSA, Fig. 2E). 
The specificity of 2’FY-RNA-5183 binding to sGP in the presence and absence of an 
unrelated RNA aptamer (RNA-569) that recognizes mouse Lcn2 (17). RNA-569, in 10 molar 
excess, did not compete for 2’FY-RNA-5183 binding to sGP (Fig. 2E). These results are 
consistent with the hypothesis that 2’FY-RNA-5183 binds sGP with specificity and high 
affinity. Cluster containing 2’FY-RNA-5183 was examined for base frequency at each position 
by APTAGUI to establish a “mutation rate” through the selections (14). 5’ end stem loop, 
which contains the poly 2’F-U-GAGC sequence motif, was identified as the most stable 
sequence. Truncations of the 2’FY-RNA-5183 were tested for binding sGP (Fig. 3A, B, D). 
These results showed that the high affinity binding element in 2’FY-RNA-5183 contains the 
poly 2’F-U-GAGC sequence motif.  
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A 2’FY-RNA-5199, a 39nt truncated version of 5199 containing the poly 2’F-U-GAGC 
sequence motif that binds sGP with Kd of 27nM was given the aptamer name of 39SGP1A. 
Further truncation to 2’FY-RNA-5199 containing only 6 U’s within the loop (Oligo 5015) had 
lower affinity for sGP, supporting the hypothesis that the structure of the U rich loop, rather 
than just the presence of a series of 2’FY modified Us, is important for binding (Fig. 3F). We 
also tested the binding of 39SGP1A with sGP by performing UV crosslinking and observed a 
clear mobility shift when the RNA and protein were combined. We confirmed that the shifted 
band was an RNA-protein photo-adduct by digestion with Proteinase K (Fig. 3C).  We also 
tested involvement of the poly 2’F-U loop by hybridizing it with antisense oligonucleotide 
DNA-5196. The presence of a 10-fold molar excess of DNA-5196 over 39SGP1A resulted in 
50% reduction in the sGP-RNA shifted band after crosslinking. These results demonstrate that 
39SGP1A is a 2’FY-RNA aptamer that bind sGP with high affinity. 
How Many Epitopes On sGP Are Recognized By The Selected 2’FY-RNA 
Oligonucleotides? 
Several RNA oligonucleotide families were identified from the NGS results that are 
not homologous in sequence. Whereas members of the family identified by the poly 2’F-U-
GAGC sequence motif bound sGP with high affinity, members of other families bound with 
lower affinity (example in Fig. 2). To establish if these oligonucleotides bound to the same or 
different protein epitopes, we tested the ability of a representative of another family to compete 
for binding of 39sGP1A with sGP.  
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The 39SGP1A aptamer, 2’FY RNA oligonucleotides 4789, 5179 and oligonucleotide 
6011, a DNA oligo that binds sGP, were used as competitors of 32P-39SGP1A for binding sGP. 
Competition was observed with all the oligonucleotides, which varied in affinity for sGP. This 
observation suggests that sGP has one favored nucleic acid binding epitope and the high 
affinity and low affinity binding is determined by the tertiary structure of the RNA (Fig.4).  
Specificity of 39SGP1A 
To establish if 39SGP1A is suitable as a sensor for early diagnosis of sGP in patient 
serum, we tested its affinity for human serum albumin (HSA).  HSA is highly abundant in 
blood, reaching concentrations up to 300 μM. The 2’FY-RNA oligonucleotide-5183, from 
which 39SGP1A was derived, bound HSA with a Kd of 400 nM (Fig. 5A). However, once 
isolated from the remainder of 2’FY-RNA-5183, 39SGP1A did not bind HSA up to 68 μM 
(Fig. 5B). 39SGP1A was also found not to bind two other highly abundant serum proteins, 
alpha 2 macroglobulin and fibrinogen (Fig. 5C).  
DISCUSSION 
In this study, we identified an RNA aptamer that binds sGP with high affinity and 
specificity. sGP is a non-structural Ebola virus 70 KDa glycoprotein that forms a parallel 
homodimer linked by disulfide bonds, which is responsible for immune modulation during 
infection (4). The choice of sGP as a SELEX target was motivated by the fact that it is secreted 
in abundance in blood early during infection, which makes it an excellent biomarker for Ebola 
infection (2). An aptamer that binds sGP could be incorporated onto a biosensor platform for 
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early infection detection. 39SGP1A is the first RNA aptamer reported to be specific for sGP. 
For our selections, we began with a complexity of 1015 2’FY modified RNA oligonucleotides. 
2’F ribose modification provides nuclease resistance and has widely been used in aptamer 
selections.  After eight rounds of selection we compared the binding of the final pool with the 
starting pool by the filter capture assay. The initial RNA pool showed no evidence of saturation 
at 5 μM, whereas in the final round RNA pool the sGP titration indicated the presence of two 
groups of oligonucleotides identified by high and low affinities. We used conventional TOPO 
TA cloning for high throughput sequencing of the 8th round and performed Next Gen 
Sequencing on 1st, 4th, 6th and 8th Round pools. Clusters obtained from high throughput 
sequencing utilizing TOPO TA cloning were identical to the clusters identified by Next Gen 
Sequencing.  
To identify potential aptamers, we searched for conserved motifs within the top 10 
clusters and identified a consensus sequence of poly U and GAGC. In the predicted secondary 
structures, the poly U stretch of 18 nts resided in the loop region followed by GAGC’s in the 
stem region. Oligonucleotides containing the poly U motif demonstrated high affinity binding 
(Kds = 20-34 nM), whereas oligonucleotides from the top ten selected clusters that did not 
contain the poly U motif bound sGP with low affinity.  Certain cellular proteins to bind to 
poly(U) rich RNA sequences (18-20).  However, the selected oligonucleotides in this study 
contained 2’F- modified pyrimidines, which alters the structure by holding the sugar ribose in 
the C3’ endo conformation. This conformation is usually favored in RNA duplexes, increasing 
the helical stability.  When oligonucleotide 5183 was prepared with 2’OH uracil and 2’F 
69 
 
 
 
cytosine or 2’ OH cytosine binding to sGP was lost, showing that 2’F-U modification is 
essential for this oligonucleotide to bind sGP with high affinity.   
A comparison of selected aptamers from libraries of RNA molecules containing 
2'amino and 2'fluoro deoxy pyrimidines resulted in higher affinity aptamers from the 2’FY 
selection. From this it was speculated that the increased affinity of 2’FY modified RNA is due 
to formation of thermodynamically stable helices and rigid structures in 2’FY RNA compared 
to the 2'amino modified RNA (12). However, X ray crystallography studies with 2’F modified 
and unmodified duplexes demonstrated that the presence of 2’F modification does not alter the 
overall helical structure of the duplex (21). The increased thermodynamic stability of the 
helices is due to the highly electronegative fluorine polarizing the nucleobases, which enhances 
the Watson-Crick pairing. Osmotic stress and X ray crystallography studies show that the 
presence of 2’Fluorine also significantly reduces the hydration of the duplex, increasing its 
hydrophobicity (22) (21). In our study also, we observed increased retention of 2’F poly U 
sequences to the hydrophobic nitrocellulose membranes in the absence of target protein in 
comparison to 2’OH RNA. Increased retention of nucleic acids to nitrocellulose membranes 
was predominantly observed with oligonucleotides containing the poly U rich sequences 
whereas past studies have reported the presence of Multi G Motifs (MGM’s) that exhibit 
significant nonspecific nitrocellulose retention (23,24).  
To localize the aptamer sequence in oligo 5183, we tested truncations, which identified 
the 5’ poly U hairpin region, which was truncated to 39 nucleotides and tested for binding to 
sGP by filter capture and EMSA assays and for the ability of a DNA oligo (5196) 
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complementary to the poly U loop reduce binding to sGP. These results confirmed that 
oligonucleotide 5199 is an aptamer with high affinity for sGP and it was name 39SGP1A. 
7\ 
and hydrogen bonding interactions among uracil (25) in comparison to GNRA (N any 
nucleotide and R purine) loops or UUCG loops, which have interactions within loop bases(26). 
39SGP1A contains an 18-nucleotide loop region comprised of 77% uracils with intermittent 
purines and pyrimidines. The effect of 2’Fluoro modification on the structure of a loop is 
unknown but, based on the reported effects of 2’FY substitution on helical stability due to base 
polarization and increased hydrophobicity, we speculate that the high affinity of the 2’FY 
modified 39SGP1A aptamer might be aided by strong intermolecular hydrogen bonding 
interactions and π-π stacking interactions between the available 2’F uracils with sGP residues. 
In addition, the 2’F- dependent structural organization within the loop is also expected to 
contribute to enhanced affinity.  
We investigated several of the selected oligonucleotides to to determine if they bind 
the same epitope on sGP in a competition assay with 32P-39SGP1A and unlabeled low affinity 
(oligo 4789), and high affinity (oligo 5179) and a DNA aptamer independently isolated 
(manuscript in preparation). These three oligonucleotides competed with 39SGP1A for 
binding sGP, which suggests that the protein has an epitope that is preferred for RNA binding. 
39SGP1A was selected as a potential sensor for early EbolaVirus infection (27), which 
would be performed with samples of patient blood. To obtain a significant signal to noise ratio 
the aptamer should not bind other serum proteins. The most abundant serum protein is albumin 
which is present in blood at concentrations as high as 300 μM. Although the selected 
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oligonucleotide, 5183, from which 39SGP1A was derived, bound to HSA with a Kd of 500 
nM, 39SGP1A did not bind HSA. Thus, truncating the oligonucleotide to a minimal critical 
sequence, appears to have eliminated structures that could bind HSA.  39SGP1A also did not 
bind α2 macroglobulin and fibrinogen, two other serum proteins which could contribute to the 
background noise.  
In summary, we report the selection of a 2’FY-RNA aptamer that binds the Ebola virus 
sGP glycoprotein with high affinity and specificity and demonstrate that the 2’F modification 
is required for binding to sGP.   
                                                                                                                                                                                                                                                                                          
MATERIALS AND METHODS 
SELEX library construction 
A DNA single stranded oligonucleotide library named 487 was synthesized by IDT (Integrated 
DNA Technologies, Coralville, IA) with the following sequence: 
5’CCTGTTGTGAGCCTCCTGTCGAA (53N) TTGAGCGTTTATTCTTGTCTCCC 3’, and 
N symbolizes equimolar mixture of A, C, G and T. The following primers were used for reverse 
transcription and PCR reactions: Oligo484:5’- 
TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3’ and Oligo 485: 5’-
GCCTGTTGTGAGCCTCCTGTCGAA-3. 
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Conversion of ssDNA SELEX library to dsDNA  
To generate starting RNA pool, an extension reaction was performed using primer 484 
and the starting ssDNA pool. 10 reactions of 1000uls each containing 2 μM 487 pool, 3.3 μM 
484 primer, 0.5 mM dNTP mix, 0.03 U/μl DNA Taq Polymerase (GenScript) in reaction buffer 
containing 50 mM KCl, 10 mM Tris-HCl (pH 8.55), 1.5 mM MgCl2, 0.1% TritonX-100 was 
incubated at 94°C for 5 min, 65°C for 15 min and 72°C for 99 min using the Multi GENE II 
PCR minicycler. The generated dsDNA was run on 2% agarose gel and purified using Qiagen 
PCR purification kit. Purified DNA was quantified via Nanodrop.  
RNA synthesis and purification  
RNA was prepared by in-vitro transcription using DurascribeTM T7 transcription kit 
from (Epicentre, Madison). Around 2nmoles of dsDNA from pool generated from extension 
is incubated with 5 mM ATP, 5 mM GTP,5 mM 2’FY UTP,5 mM 2’FYCTP, 5 mM DTT, 
0.2U/μL  T7 Enzyme in a total volume of 2.8 mL and 5% DMSO and incubated at 37°C for 4 
h. DNA mixture was then digested with 1 MBU DNAse I. The RNA was resolved through a 
7M urea 8% (19:1 acrylamide:bisacrylamide) gel in 1X Tris Borate EDTA buffer, pH 9.1 to 
separate the residual NTPs and abortive transcripts. Transcribed RNA was eluted in TE buffer 
(10 mM Tris-HCl, 1 mM EDTA pH 8.0) for 18 h at 37°C.  
In-vitro selection of RNA aptamers against sGP (soluble glycoprotein)  
In vitro selection of an aptamer for sGP was carried out by SELEX (Systematic 
Evolution of Ligands by EXponential enrichment). Prior to the first round of selection, a 
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dsDNA pool was generated from a library of ssDNAs (487D pool) by primer extension. 
Starting RNA pool was generated by in-vitro transcription using dsDNA (487D) pool as 
template. RNA pool (1X1015 molecules) 2nmoles was incubated with sGP and the non-binding 
RNA sequences were partitioned by passing it through nitrocellulose membrane. For each 
positive selection, to increase the stringency of selection ratio of RNA pool: sGP was 
increased. To remove nonspecific membrane binders negative selections were performed 
against the nitrocellulose membrane. Reverse transcribed polymerase chain reaction (RT-PCR) 
amplification was used to generate DNA for subsequent selection rounds. 8 rounds of 
selections were performed including negative and positive selections.  Enriched pool from the 
10th SELEX round was cloned into the TOPO XL PCR cloning plasmid for sequencing, in 
addition PCR libraries were prepared for Next Gen Sequencing using Illumina sequencing 
primers.  
Nitrocellulose capture assay  
To determine the binding affinity of sGP to RNA aptamers, 5’P32 end labeled RNA 
was firstly prepared. 2’FY modified RNA was transcribed using Durascribe transcription kit 
(Epicentre Technologies), transcribed RNA was electrophoresed in an 8% polyacrylamide–7 
M urea gel, and eluted from the gel. RNA was dephosphorylated with calf intestine 
phosphatase for 1 h at 37°C, extracted with phenol, and precipitated with ethanol. The RNA 
was end-labeled with [γ-32P] ATP and T4 polynucleotide kinase.  To determine the binding 
affinity of the RNA aptamer 5183 to sGP, binding studies were performed by first denaturing 
the 2nM RNA at 95 degrees for 5 mins followed by refolding in binding buffer [137 mM NaCl, 
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2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 5 mM MgCl2, pH 7.4] at RT for 30 min. RNA 
was incubated with varying concentrations of sGP (10 nM-1 μM) at RT for 30 min. The RNA 
sGP complex was passed through nitrocellulose membranes (HAWP 02500) and filters were 
washed with 3 mL binding buffer and later quantified using Liquid Scintillation Counter. The 
data was fit to F=Fmin+(Fmax*L^n)/(L^n+Kd^n) to determine the Kd. 
Electrophoretic mobility shift assay (EMSA) 
Binding reactions performed by firstly by denaturing of 32P- 5’ end labeled RNA at 95 
degrees for 5mins followed by slow cooling in binding buffer [137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, 5 mM MgCl2, pH 7.4] for 30 min. Refolded RNA was 
incubated with sGP in binding buffer for 30 min at room temperature.  The mixtures were 
analyzed for complex formation by resolution through a 6% native polyacrylamide gels run in 
Tris HEPES EDTA buffer (33 mM Tris, 66 mM HEPES, 0.1 mM EDTA-Na, pH 7.5) at 200V 
and the 32P was visualized using a phosphor imager. 
Competition binding assay  
Competitive binding reactions were performed by incubating 4 μM sGP with 18 μM 
competitor RNA sequences for 30 min at RT in binding buffer. Following the preincubation 
period, 32P-labeled 39sGP1A 2’FY-RNA was added to the reaction mix to a final concentration 
of 200 nM and the samples were incubated for 15 min.  The RNA protein complexes were then 
UV crosslinked at 365 nm for 15 min. Crosslinked products were run on 10% SDS PAGE 
reducing gel, the gel was dried and later imaged by Typhoon scanner and quantification was 
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performed using Image J software. 39sGP1A RNA aptamer was tested individually against 
39sGP1A, 5179, 4789 and 6011 oligonucleotides. 
Incorporation of 4 Thio UTP and RNA protein UV crosslinking 
RNA was invitro transcribed in the presence of 2’F-UTP and 4-thio-uridine 
5’triphosphate (Trilink Biotechnologies) at a molar ratio of 1:1) and radiolabeled with P32-γ-
ATP by T4 polynucleotide kinase. 3 pmol of RNA was denatured at 95°C for 5 min followed 
by snap cooling on ice for 5 min. The RNA was folded in PS Buffer (137 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 5 mM MgCl2, pH 7.4) for 10 min at RT. To link sGP 
to the 2’FY-RNA aptamer 5183, 3 pmol 2’FY-RNA was incubated with 15 mol sGP in 15 μL 
binding buffer for 20 min at RT for complex formation. This mixture was irradiated for 6 min 
and 12 min under a UV lamp (365 nm) with the samples placed 3 cm from the lamps. RNA-
sGP samples were treated with proteinase K for 30 min. The samples were later resolved 
through a 10% reducing SDS PAGE gel to separate the 2’FY-RNA-protein complex, free 
2’FY-RNA and free protein. The 32P on the gel was visualized using a phosphor imager. 
Antisense competition assay with DNA oligo 
39sGP1A RNA aptamer was transcribed using Durascribe T7 transcription kit, RNA 
transcript was dephosphorylated using alkaline phosphatase (Promega 1U) at 37°C for 1 h, 
followed by phenol chloroform extraction. The dephosphorylated 2’FY-RNA was 5’ end 
labeled with 32P by incubating with T4 polynucleotide kinase (NEB) at 37°C for 30 min 
followed by 65°C for 15 min to inactivate the enzyme. The labeled RNA aptamer was 
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denatured at 95°C for 5 min followed by snap cooling on ice for 5 min and then incubated at 
RT for 10 min in (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 5 mM 
MgCl2, pH 7.4). The folded RNA was incubated in the presence and absence of 5-fold excess 
of oligonucleotide 5196 for 20 min then sGP was added and the samples incubated for 30 min. 
The samples were then irradiated for 15 min UV (365nm) at 3 cm distance from the lamp. The 
samples were later resolved through a 10% reducing SDS PAGE gel to separate the 2’FY-
RNA aptamer-protein complex, free RNA and free protein. The 32P on the gel was visualized 
using phosphor imager. 
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 LEGENDS TO FIGURES 
Figure 1. Next Gen Sequencing Analysis and Consensus Motif Identification. A) The 
frequency of singletons, enriched and unique sequences for each SELEX round B) The SELEX 
protocol for selecting 2’FY-RNA aptamers with high affinity for sGP C, D) The frequency of 
base occurrence in each position for the 1st and 9th round pools showing evidence of sequence 
enrichment during selection E) A conserved sequence motif is identified among the top 
identified clusters. 
Figure 2. The Affinities of Selected 2’FY-oligonucleotides for sGP. A) The concentration 
dependence of sGP binding to 2 nM 32P-5183 as a 2’FY-RNA and an RNA oligonucleotide. 
The estimated Kd was for the 2’FY-RNA was 50 nM. B) An extended sGP titration up to 3 
μM against 2nM nM oligonucleotide 32P-5183 to validate saturation of the binding curve, C) 
The concentration dependence of sGP binding to 20 nM  
32P- oligonucleotide 4789. The estimated Kd was 500 nM.  D) M fold predicted secondary 
structures of oligonucleotide s 4789 and 5183 E) Electrophoretic mobility shift assay with 100 
nM 32P- oligonucleotide 5183. Buff, buffer only. sGP, buffer plus 2 μM sGP. comp, buffer 
plus 2 μM sGP and 10 μM Lcn2 aptamer. 
Figure 3. Determining the Binding Epitope for sGP on the 2’FY RNA aptamer. 
A) A mutation count chart created in APTAGUI to determine the mutation frequency for 5183 
at each nucleotide position, B) The M-fold predicted secondary structures of truncations of 
5183, C) UV crosslinking of 200 nM 32P 39SGP1A to 2.5 uM sGP followed by treatment with 
or without proteinase K, D) Binding of 10nM 32P-oligo 5183 truncated oligonucleotides to 
50nM and 500nM sGP, E) Binding of  0.5 uM  32P-39SGP1A to 10uM sGP in the presence of 
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5 uM antisense oligonucleotide 5196, which is complimentary to the loop region of 
oligonucleotide 39SGP1A, F) Concentration dependence of sGP binding to 10nM 32P- 
oligonucleotide 39SGP1A and 10 nM 32P- oligonucleotide 5015. The estimated Kd was 27nM 
for 39SGP1A 
Figure 4. Competition Binding Assay to Determine if the Selected Aptamers Bind to the 
Same Protein Epitope. 32P- oligonucleotide 39SGP1A (0.2 μM) was incubated for 15 min at 
23°C with a 10-fold excess of the identified oligonucleotides. The samples were stabilized by 
UV crosslinking and resolved by SDS-PAGE. 
Figure 5. Specificity of 2’FY-5183 and 39SGP1A for sGP. A) Binding of 2 nM 2 
’FY 5183 protoaptamer to human serum albumin (HSA) B) Binding of the 10nM 32P 2’FY 
39SGP1A aptamer to HSA C) Lack of affinity of 10 nM 2’FY 39SGP1A for human serum 
albumin (200 nM to 50 μM), fibrinogen (200 nM to 4 μM) or α2macroglobulin (200 nM to 5 
μM). 
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Figure 1 
 
 
 
Next Gen Sequencing Analysis And Consensus Motif Identification 
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Figure 2 
 
 
 
The Affinities of Selected 2’FY-oligonucleotides for sGP.  
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Figure 3 
 
 
 
Determining the Binding Epitope for sGP on the 2’FY RNA Aptamer. 
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Figure 4 
 
 
 
Competition Binding Assay to Determine if the Selected Aptamers Share a 
Protein Epitope 
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Figure 5 
 
 
Specificity of 2’FY-5183 and 39SGP1A for sGP. 
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ABSTRACT 
Ebola viruses (EBOV) cause severe disease in humans and in non-human primates in the form 
of viral hemorrhagic fever. Ebola virus is also of public health concern as a potential 
bioterrorism organism for which no vaccine or anti-viral is available. Fast-acting and 
prophylactic therapeutics are needed to reduce mortality. In view of the paucity of current 
antiviral therapies for EBOV we undertook to select an aptamer against the EBOV surface-
exposed glycoprotein, GP1. Here we described the selection and characterization of several 
2’FY RNA aptamers that recognize the GP1,2 heterotrimer. One aptamer recognizes the 
heterotrimer with the mucin domain included, which is the form of the protein found on the 
circulating virion. Another aptamer recognizes the GP1,2 heterotrimer lacking the mucin 
domain of GP1, which is the form of the protein in the endosomes that mediates entry into the 
cytoplasm. Thus, these aptamers target the virion in two stages of infection and together might 
be effective in preventing the interaction between virus and the host cell and viral entry into 
the cytoplasm, thereby reducing viremia and spread of the virus to others.  
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INTRODUCTION 
Ebola Virus (EBOV) and Marburg Virus (MARV) are members of the family Filoviridae of 
enveloped viruses with a non-segmented negative strand RNA genome. Filoviruses cause 
sporadic outbreaks of hemorrhagic fever in human and non-human primates in Africa with 
fatality rates up to 90%.  Filovirus hemorrhagic fever is associated with high levels of 
inflammatory cytokines and coagulation disorders resulting in septic shock and multiorgan 
failure (1). The virus is transmitted through contact with bodily fluids and can infect various 
cell types across different host species. They typically infect hepatocytes, dendritic cells, 
endothelial cells, macrophages, and monocytes (2). The viral genome encodes seven structural 
proteins: envelope glycoprotein (GP), major matrix protein (VP40), nucleoprotein (NP), 
polymerase cofactor (VP35), replication/transcription protein (VP30), minor matrix protein 
(VP24), and RNA dependent DNA polymerase (L) (3). The viral replication cycle involves 
attachment of the virus to its receptors, uptake of the virus, intracellular trafficking of the virus 
in the endosome and release of the nucleocapsid into the cytoplasm, synthesis of viral proteins, 
assembly and budding from the cell surface (4).  
Viral glycoprotein (GP1) is a homotrimer, forming spikes on the surface of the virus and is the 
only protein on the EBOV viral particle surface.  Folding and assembly of GP1 occurs 
independently of other viral proteins (5). It is initially synthesized as a precursor that is later 
cleaved by the proprotein convertase, furin, into GP1 (140kD) and GP2 (26kD) that are linked 
by disulfide bonds (6). The GP2 subunit contains two heptad repeat regions, which facilitate 
assembly of GP into trimers, a transmembrane anchor sequence, and the fusion loop (5). The 
GP1 subunit contains the receptor binding site and a heavily glycosylated mucin domain. The 
91 
 
 
 
residues responsible for mediating interactions between GP1 and the host cell are in the 230-
residue N-terminal domain of GP1. The crystal structure of EBOV GP demonstrates that the 
receptor binding site of GP1 is masked by the glycan cap created by the mucin domain (7). 
Consistent with this structure is the observation that deletion of the C-terminal mucin domain 
enhances viral infectivity in vitro (8-10).  
Ebola viruses infect a broad range of cells and a host of proteins are known to enhance viral 
entry into the host cells including the C-type lectins L-SIGN, DC-SIGN and the tyrosine kinase 
receptor Axl (11-14). Infectivity involves at least two recognition events 1) endocytosis at the 
host cell surface and 2) cytoplasmic entry in the endosome. The cell surface receptor for EBOV 
is believed to be the T-cell immunoglobulin and mucin domain 1 (TIM-1) receptor (15). The 
usual function of the TIM-1 receptor is to bind phosphatidyl serine on the surface of apoptotic 
cells and facilitate their phagocytosis (16). TIM-1 also facilitates the entry of Dengue Virus by 
directly interacting with the virion-associated phosphatidylserine (17). Structural studies of the 
TIM immunoglobulin domain have demonstrated that phosphatidyl serine binds in a cavity 
built up by the CC’ and FG loops termed the metal ion-dependent ligand binding site (MILIBS) 
(17). By contrast with the Dengue virus interaction, TIM-1-mediated Ebola infection depends 
on a direct interaction between the viral glycoprotein GP through residues in the ARD5 
domain, which is outside of the TIM-1 phosphatidylserine binding pocket and does not include 
the MILIBS (15). This specificity was demonstrated by showing that the anti-TIM antibody, 
which binds the ARD5 epitope, completely blocked EBOV entry to Vero cells, whereas A6G2 
antibody, which prevents TIM-1 binding to phosphatidyl serine, was much less effective in 
blocking the viral transduction (15). Co-immunoprecipitation studies also showed that there is 
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direct interaction between Ebola GP and TIM-1 that depends on the receptor binding domain 
(15). However, later it was discovered that phosphatidyl serine on the virus surface directly 
binds TIM-1 thereby promoting virion internalization (18).  
The endosomal receptor for EBOV is believed to be Niemann-Pick C1(NPC1), a lysosomal 
cholesterol transporter (19). The binding site for C1(NPC1) is exposed after endosomal 
cysteine proteases cleave EBOV GP1 to remove the heavily glycosylated C terminal region to 
generate an entry intermediate comprising of the N terminal of GP1 and GP2 (19,20). 
Mutations in the C1(NPC1) binding site on GP1 decrease viral entry (19).  
In this study, we report the selection and characterization of 2’FY RNA aptamers against 
GP1,2 delta mucin and full length GP1,2 glycoproteins. Together these aptamers are expected 
to thwart interactions between virion and host at two stages. The GP1,2 delta mucin 
conformation with exposed RBD interacts with NPC-1 in the endosome. Therefore, an RNA 
aptamer against the GP1,2 delta mucin could intercept the viral host interaction at that step. In 
addition, TIM-1 is not expressed by all EBOV permissive cell lines ,(18), which suggests the 
occurrence of other unidentified cellular receptors for EBOV. In this situation, an RNA 
aptamer against of GP1,2 full length will be effective in preventing viral replication.   
RESULTS 
SELEX and Analysis 
To identify aptamers that bind Ebola GP1,2 we performed two SELEX experiments in which 
early rounds selected against the purified recombinant protein and later rounds were against 
the protein in the context of the viral particle (Fig. 1).  GP1,2 lacking the mucin domain 
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(GP1,2Δmucin) was used in the early rounds of SELEX 1280 and the full length GP1,2 was 
used in the early rounds of SELEX 1281 (Fig. 1A,D). In both protocols, later rounds were 
selected against Vesicular Stomatitis Virus (VSV) pseudotyped with GP1,2Δmucin 
(SELEX1280) or GP1,2 (SELEX1281).Next Gen Sequencing results from both protocols 
showed evidence of expanding potential aptamer populations with a reduction in unique 
sequences from early to late rounds, which indicates population expansions (Fig. 1B, E). The 
progress of oligonucleotide selection evaluated from frequency plots for each round in which 
the number (counts) of each base (Y axis) is plotted for each base position in the 
oligonucleotide length (X axis). The frequency plots show that a different population emerged 
in SELEX1280 after switching the selection from the protein to the virus particles, whereas 
this did not happen in SELEX1281 (Fig. 1C, F). We selected the top 10 enriched classes from 
each SELEX experiment for further study. 
From the SELEX experiments we identified clusters of selected sequences families using the 
APTAGUI web application. To further identify which clusters likely contained high affinity 
aptamers, oligonucleotides representing the top 10 sequence clusters found for SELEX 1280 
were mixed in equal amounts and incubated for 15 min with VSV alone or VSV pseudotyped 
with GP1,2Δmucin (RNA/Protein =10:1). The samples were then spun through a sucrose 
cushion to separate the RNAs bound to the virus particles from the unbound RNAs. The 
collected RNAs were cloned and sequenced. Oligonucleotides 4789 and 4796 were the most 
highly represented of oligonucleotides that remained associated with the virus particles through 
the sucrose cushion, summing to 47% of the clones from the GP1,2Δmucin-VSV population 
(Fig. 2). These oligonucleotides also had the highest selective binding to the GP1,2Δmucin-
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VSV captured population, being represented 3-4.5 times as much with GP1,2Δmucin-VSV 
than with the VSV control particles.  
The Dissociation Constant (Kd) of Selected Proto-Aptamers  
Oligonucleotides 4789 and 4796 (SELEX 1280), identified from the sucrose centrifugation 
assay, were tested for their affinities for the GP1,2 delta mucin recombinant and GP1,2 full 
length recombinant proteins using the nitrocellulose filter capture assay. Oligonucleotide 4789 
bound GP1,2Δmucin with a Kd of 140nM but did not bind the full length GP1,2 glycoprotein 
(Fig. 3A). These results suggest that 4789 binds to an epitope on GP1,2 that is inaccessible in 
the presence of mucin domain. The interaction between oligonucleotide 4789 and GP1,2 was 
also demonstrated by EMSA in which a shifted band was observed when the RNA was 
incubated with GP1,2Δmucin. The specificity of oligonucleotide 4789 binding for 
GP1,2Δmucin was also testing with BSA for which no binding was observed. (Fig. 3B). 
 4797 oligonucleotide sequence appeared in the top clusters of both SELEX 1280 and 1281 
and was tested for its binding to GP1,2 full length and GP1,2 delta mucin recombinant protein. 
Interestingly, it bound neither protein. This sequence appeared in the top clusters, which were 
performed over different time periods.  This might be an example of the evolution of a “sticky” 
oligonucleotide that binds nonspecifically to many surfaces such as the nitrocellulose 
membrane used for particle capture. The “sticky” nature of this oligonucleotide is also 
consistent with the observation that 4797 pelleted predominantly with VSV control particle 
when passed through a sucrose gradient.  
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Oligonucleotides 5185, 5186, 5187 and 5188 sequences selected in SELEX 1281 in but not in 
SELEX 1280 were tested for binding to the GP1,2 full length protein.  The affinities (Kd) of 
these oligonucleotides were 50 nM, 120 nM, 560 nM and 300 nM for 5185, 5186, 5187 and 
5188 respectively.  These oligonucleotides tested for binding to the isolated GP1,2 proteins 
were further evaluated for their ability to bind virus particles pseudotyped with full-length 
GP1,2 and with control virus particles lacking GP1,2. Oligonucleotide 5185 bound GP1,2 full 
length glycoprotein with a Kd of 50 nM  and it also bound the GP1,2 pseudotyped virus 
particles in a titration that achieved saturation. (Fig.4). 
DISCUSSION 
Aptamers have notable advantages over antibodies that include non-immunogenicity, in-vitro 
production and stability (21).A variety of aptamers have been selected to counter host-virus 
interactions by targeting different viral proteins (21-23). Examples include: 1) An RNA 
aptamer that recognizes HIV-GP120 that effectively neutralizes clinical isolates of HIV (24), 
2) Viral RNA-dependent RNA polymerases with basic patches that permit easier selection of 
an RNA aptamer (25), and 3) the internal ribosome entry site (IRES), a structured RNA region 
in the viral mRNA that binds the ribosome and initiates cap-independent translation to favors 
viral protein translation. Aptamers targeting the IRES inhibit IRES-dependent translation of 
HCV proteins (26). These cited aptamers were selected to counter host–virus interactions by 
targeting viral components.   
In this study 2’FY modified RNA aptamers were identified that bind to two conformations of 
Ebola glycoproteins which could be used to thwart viral host cell interactions.  SELEX 1280 
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was performed against GP1,2 Δmucin and SELEX1281 was performed against full length 
GP1,2. We employed Next Gen Sequencing (NGS) of the random region of several SELEX 
populations to identify expanding potential aptamer populations. NGS has the advantage over 
conventional sequencing that it provides up to 130 million sequence reads and, with barcoding, 
multiple rounds can be sequenced simultaneously. In these SELEX experiments, reduction in 
unique sequences from 87% to 23% of the total between the 2nd and 5th rounds demonstrated 
selection for a subset of sequences. The 9th round involved selection against virus particles and 
the frequency plot showed that a different population emerged in this round for SELEX 1280. 
This change in dominant populations may be due to the elimination of oligonucleotides that 
bound to surfaces on the viral protein other than the protein surface exposed on the virus 
particles. In contrast, there wasn’t much increase in the percentage of unique sequences in 
round 9. The unique oligonucleotide sequences are expected to be oligonucleotides that bind 
weakly to the protein or that do not bind and that were therefore retained through the washing 
during filter capture.  
For SELEX 1281, 1st, 4th, 5th, 8th and 10th rounds were barcoded by PCR and sequenced. 27 
million reads were obtained with same number of sequences obtained from each round. The 
uniqueness declined from each round, with the first round having 99.6% in the unique fraction 
and the percent of unique sequences reduced with each cycle. The last round of selection had 
25.9% unique sequences. Reduction in the unique fraction in both SELEX experiments clearly 
suggests that sequences were enriched as we moved along in the selection process. In contrast 
to SELEX1281, in which there was change in the frequency plot when the target was changed 
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from protein to virus particle expressing protein, no change in population was observed when 
the target was changed from recombinant GP1,2 to virus particles expressing GP1,2.  
Our overall goal was to obtain RNA aptamers that can be applied in the blood in which they 
must remain associated with the viral particles in the presence of shear stress. Therefore, 
selection was performed under conditions that apply sheer to the aptamer-viral complexes. The 
RNAs bound to viral particles were spun through a sucrose cushion to identify RNAs retained 
on the virus particles after subjection to shear stress. For this assay the top ten potential 
aptamers identified from SELEX 1280 were mixed at concentrations to achieve high 
RNA/Protein (10:1). Centrifugation was for an hour to select for aptamers that form complexes 
with slower koffs (27). The kinetic half-lives of aptamer protein complexes with pM Kd’s 
range from 6 min to 60 mins.   
Using this method, we selected for oligonucleotides with the sequences 4789 and 4796 that 
preferentially bound to the GP1,2Δmucin pseudotyped VSV virus particles. Oligonucleotide 
4789 bound to GP1,2 Δmucin with a Kd of 143 nM and it showed concentration dependent 
saturation binding against GP1,2Δmucin virus particles. We did not observe any binding with 
the VSV control virus particles. From the top clusters obtained from SELEX 1281, we tested 
the binding of oligonucleotides 5185, 5186, 5187 and 5188 to full length GP1,2. All the 
oligonucleotides bound to full length GP1,2 with different affinities. Among these, 
oligonucleotide 5185 bound full length GP1,2 with high affinity (50 nM) Kd and also bound 
the GP1,2 pseudotyped virus particles. Thus, from the binding assay and sucrose centrifugation 
assay we can conclude that oligonucleotides 4789 and 5185 are sequences that bind to 
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GP1,2Δmucin and full length GP1,2 conformations, in recombinant form and when expressed 
on virus particles.  
GP1,2 interacts with the NPC-1 receptor in endosome in low pH conditions therefore the next 
step in the development of these aptamers will be to test the sensitivity of the aptamer-GP1,2 
interaction at low pH. The identified oligonucleotides that bind full-length GP1,2 pseudotyped 
virus particles will be tested to determine if they prevent viral replication using an in vitro 
transduction assay. Once an aptamer that reduces viral infectivity in vitro has been identified, 
the efficacy of these aptamers against the viruses will be determined in an in vivo assay. If 
these identified oligonucleotides that bind to the GP1,2 proteins do not prevent viral 
transduction they could still be used as drug and anti-viral agent carriers to tag along with the 
virus particles and target the cells that are also targeted by the virus (28,29). They could also 
be developed for diagnostic purposes (21,30). For EBOV, a rapid diagnosis of infection is 
required because, after the appearance of symptoms, the patient succumbs to infection in 10 
days. The current methods for diagnosis of EBOV are RT-PCR and ELISA (31). But these are 
time consuming assays that require sophisticated and expensive equipment. The necessary 
equipment for these assays is generally lacking in regions of EBOV occurrence. Aptamers are 
compatible with inexpensive analytical equipment that could be readily used in field to detect 
EBOV and other analytes.  
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MATERIALS AND METHODS 
SELEX library construction 
DNA single stranded oligonucleotide library named 487 was generated 
5’CCTGTTGTGAGCCTCCTGTCGAA (53N) TTGAGCGTTTATTCTTGTCTCCC 3’, and 
N symbolizes an equimolar mixture of A, C, G and T. It was synthesized by Integrated DNA 
Technologies, Coralville, IA. Primers given below were used for reverse transcription and PCR 
reactions.  
484:5’TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3’ and 
485: 5’-GCCTGTTGTGAGCCTCCTGTCGAA-3. 
Conversion of ssDNA SELEX library to dsDNA 
To generate a starting RNA pool, an extension reaction was performed using primer 
484 and the starting ssDNA pool. 10 reactions of 1000 μL each containing 2uM 487 pool, 
3.3uM 484 primer, 0.5 mM dNTP mix, 0.03 U/μL DNA Taq Polymerase (GenScript) in 
reaction buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 8.55), 1.5 mM MgCl2, 0.1% 
TritonX-100 was incubated at 94°C for 5 min, 65°C for 15 min and 72°C for 99 min using the 
Multi GENE II PCR minicycler. The generated dsDNA was run on 2% agarose gel and purified 
using Qiagen PCR purification kit. Purified DNA was quantified using a Nanodrop 
spectrophotometer.  
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RNA Synthesis and Purification 
RNA was prepared by in-vitro transcription using a DurascribeTM T7 transcription kit 
(Epicentre, Madison). Around 2 nmole of dsDNA from a pool generated from extension was 
incubated with 5 mM ATP, 5 mM GTP, 5 mM 2’FY UTP, 5 mM 2’FY CTP, 5 mM DTT, 0.2 
U/μL of T7 polymerase in a total volume of 2.8 mL and 5% DMSO and incubated at 37°C for 
4 h. The DNA was then digested with 1MBU of DNAse I and the remaining RNA was resolved 
through an 8% (19:1 acrylamide:bisacrylamide) acrylamide gel in 7M urea, Tris Borate EDTA 
buffer (TBE buffer 89 mM Tris, 89 mM Boric acid and 2 mM EDTA) pH 9.1 to separate 
residual NTPs and abortive transcripts. The transcribed RNA was eluted in 10 mM Tris-HCl, 
1 mM EDTA pH 8.0 for 18 h at 37°C and concentrated by ethanol precipitation.  
In-Vitro Selection of RNA Aptamers That Bind Ebola Virus Particles and Glycoproteins 
SELEX was performed against GP1,2 full length glycoprotein SELEX 1281 and GP1,2 
mucin domain deleted glycoprotein (SELEX1280).   A ssDNA pool with a complexity of 453 
sequences from IDT Technologies was used as starting pool.  This pool was designated as 487, 
with each draw from the tube identifying the subset of oligonucleotides with a different letter 
(487A and 487D were used here). Constant regions that flank the 53-base central region of 
random sequence in pool 487 are complementary to primers 484 and 485. In the first round of 
SELEX, DNA polymerase catalyzed extension copied the ssDNA to produce dsDNA from the 
forward primer TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA (484), 
which contains a T7 promoter. The DNA was in-vitro transcribed using T7 RNA polymerase, 
2’ fluoro-labeled pyrimidine triphosphates, and unmodified purine triphosphates. The resulting 
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complexity was about 1015 RNA sequences.  The RNA pool was incubated with the GP1 full 
length and mucin domain deleted trimer at a 1:1 ratio and the complexes collected on a 
nitrocellulose filter that allowed the free RNA (non-binders) to pass through. RNA bound to 
the protein was eluted from nitrocellulose membranes by 7M urea was purified through ethanol 
precipitation. Purified RNA was reverse transcribed and the cDNA was amplified by PCR 
under conditions that promote low fidelity transcription. 
For SELEX 1280 in each of the successive rounds the concentration of the protein was 
reduced by 10% to increase the selection stringency. Nine rounds of selection were performed 
of which the first 7 rounds were done with soluble trimers followed by three rounds of negative 
selections and the final selection was done using GP1,2 pseudotyped VSV virus particles. The 
2nd, 5th, 8th and 9th rounds were barcoded by PCR amplification using primers containing the 
barcode sequences and obtained 97 million sequences from the sequencing. 
Similarly, for SELEX 1281 for each successive round the concentration of protein was 
reduced by 10%, 4 rounds of positive selections were performed including negative selections 
against the nitrocellulose membrane. 8th and 9th round involved selection against VSV virus 
particles pseudotyped with GP1,2 full length glycoprotein. Final 10th round selection was 
against virus particles lacking GP1,2 to eliminate nonspecific binders. 1st, 4th, 5th, 8th and 10th 
rounds were barcoded by PCR amplification and we obtained 24 million sequences from 
sequencing.  
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Filter Capture Assay  
To determine the binding affinity of GP1,2 recombinant proteins to RNA aptamers, 5’ 
32P end labeled RNA was prepared. The 2’FY modified RNA was transcribed using a 
Durascribe transcription kit (Epicentre Technologies), separated by electrophoresis through an 
8% polyacrylamide gel in the presence of 7 M urea, and eluted from the gel. The RNA was 
dephosphorylated by incubation with calf intestine phosphatase for 1 h at 37°C, extracted with 
phenol, and precipitated with ethanol. The RNA was 5’ end-labeled with [γ-32P] ATP and T4 
polynucleotide kinase.  In preparation to determine its binding affinity for GP1,2 and other 
proteins, the RNA (2 nM) was incubated at 95°C for 5 min followed by refolding in binding 
buffer [137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 5 mM MgCl2 pH 7.4] 
at room temperature (RT; 22-24 degree Celsius) for 30 min. The folded RNA was incubated 
with varying concentrations of GP1,2 (10 nM-1 μM) at RT for 30 min. The RNA GP1,2 
complex was captured by passing the reaction mixture through nitrocellulose membranes 
(HAWP 02500) and washing with filters 3 mL of binding buffer. Quantification of 
RNA/protein captured on the filter was by liquid scintillation counting. To determine the Kd 
the data was fit to F=Fmin+(Fmax*L^n)/(L^n+Kd^n) (32). 
Electrophoretic Mobility Shift Assay (EMSA) 
Binding reactions performed with 5’ end labeled RNA that is first denatured at 95°C 
for 5 min followed by slow cooling in binding buffer (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2 mM KH2PO4, 5 mM MgCl2, pH 7.4) for 30 min. 5uM Refolded RNA was 
incubated with 0.5uM of recombinant GP1,2 delta mucin or 0.5uM BSA in binding buffer for 
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30 min at room temperature. Mixtures were analyzed for complex formation by resolving them 
through a 6% (37.5:1 acrylamide:bisacrylamide) )native polyacrylamide gels run in Tris 
Acetate EDTA buffer (6.75 mM TrisCl, 1 mM EDTA, 3.3 mM sodium acetate) (pH 7.4) @ 
200V followed by quantification of the 32P on the gel using an X ray film.  
Determination of Total Protein and Percent Glycoprotein on Virus Particles 
Total viral protein content was measured using Bradford assay using a standard series 
of BSA concentrations 1:150 dilutions of GP1,2 pseudotyped virus particles (in duplicates). 
The pseudotyped virus particles were also resolved by 10% SDS PAGE along with a known 
concentration of recombinant EBOV GP1, 2 (Purchased from BPS biosciences). The gels were 
stained with Coomassie blue and the bands quantified by Image J. The amount of GP1,2 in the 
particles was determined relative to the control the GP1,2 control and then converted to a 
percent of total protein on the virus particles using the results from the Bradford (Coomassie 
blue) assay for total protein.  
 
ACKNOWLEDGEMENT 
Financial support for this study was provided by NIH grant R21AI106329-01 to MNH. 
 
 
 
 
104 
 
 
 
 
LEGENDS TO FIGURES 
Figure 1 Comparison of top 10 sequences from SELEX experiments to select aptamers 
that recognize GP1,2Δmucin and full length GP1,2  
A,D) Flow charts depicting the sequential selection steps for each SELEX experiment. 
Downward arrows represent positive selection steps and horizontal arrows represent negative 
selections. B,E) Frequency chart of SELEX 1280 (B) and SELEX 1281 (E) depicting the 
frequency of singletons, enriched and unique fraction.  C,F) Frequency chart of the random 
region of each round of SELEX 1280 (C) and SELEX 1280 (F) 
Figure 2 Selection through a sucrose cushion 
The oligonucleotides listed in the abscissa were spun through a 20% sucrose cushion in the 
presence of either control VSV particles or VSV particles pseudotyped with GP1,2Δmucin. 
The oligonucleotides in the pellet were sequenced to determine the fractional frequency of 
each oligonucleotide. The dashed at 0.1 represents the fractional frequency expected if an 
oligonucleotide were not preferentially pelleted with the particle. The asterisks identify two 
oligonucleotides that preferentially pelleted with the VSV particles pseudotyped with 
GP1,2Δmucin 
Figure 3 Filter capture assay to estimate the affinity of oligonucleotide 4789 for 
GP1,2Δmucin 
A) Titration of full length GP1,2 and GP1,2Δmucin recombinant proteins against 2 nM 32P-
4789 2’FY-RNA by filter capture assay to establish the Kds, which was ND (not determined) 
for GP1,2 and 143nM GP1,2Δmucin, respectively B) EMSA analysis with 5uM 32P-4789 
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2’FY-RNA and 0.5 μM BSA, 0.5 μM GP1,2 delta mucin or 64 ng/ul VSV –GP1,2Δmucin 
virus particles. The arrows show the positions of the mobility shifted RNA associated with 
virus particles (V) and recombinant protein (P). C) Titration of GP1,2Δmucin-pseudotyped  
VSV virus particles or VSV virus particles lacking GP1,2 against 10nM 32P-4789 2’FY-RNA 
by filter capture. 
Figure 4 Filter capture assay to determine the affinity of oligonucleotide 5185 and 5187 
for GP1,2 
A) Titration of full length GP1,2 against 10 nM 32P-5185 2’FY RNA measured by the filter 
capture assay from which the estimated Kd was 50nM. B) Titration of full length GP1,2 
pseudotyped VSV particles against 10 nM 32P-5185 2’FY RNA measured by the filter capture 
assay. C) Titration of full length GP1,2 against 10 nM 32P-5187 2’FY RNA measured by the 
filter capture assay from which the estimated Kd was 560nM. 
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Figure 1 
 
 
 
Comparison of top 10 sequences from SELEX experiments to select aptamers that 
recognize GP1,2Δmucin and full length GP1,2 . 
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Figure 2 
 
 
 
 
Selection through a sucrose cushion 
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Figure 3 
 
 
 
Filter capture assay to estimate the affinity of oligonucleotide 4789 for GP1,2Δmucin 
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Filter capture assay to determine the affinity of oligonucleotide 5185 and 5187 for GP1,2 
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CHAPTER 4 
CONCLUSION AND DISCUSSION 
Ebola viruses are highly pathogenic viruses that infect humans and non-human 
primates with very high mortality rates. The first Ebola virus outbreak was reported in 1976 
and there have been sporadic outbreaks reported over the years. However, there still aren’t any 
commercially available vaccine or therapeutic drugs against Ebola viruses. During the 
devastating outbreak of Ebola Viruses in 2014, many candidate vaccines were introduced and 
are still in clinical trials. In addition to vaccines, several therapeutic drugs against Ebola virus 
were also expeditiously put under investigation for efficacy that are still in clinical trials. Aside 
from the lack of tested therapeutics for Ebola virus, another pressing concern is the inability to 
detect early virus infections. The available diagnostic kits are mostly antibody based and detect 
the serum antibodies against Ebola virus, which take time to appear, or the viral RNA, which 
requires correct timing of blood sampling.  [1, 2]. Due to limitations, such as those just 
mentioned, associated with the current detection kits there is still a need for robust, cost 
effective and sensitive technique for early detection of Ebola viruses. Aptamers have been 
established as a potent alternative to antibodies.  Several aptamers have been selected by others 
to function either as an antiviral or for biomolecule detection [3-5]. 
This thesis describes efforts to select and characterize 2’FY-RNA aptamers to Ebola 
Glycoproteins (sGP and GP1,2) with the expectation that the aptamers will have applications 
for intervention of viral host interaction and/or integration onto a biosensor platform. We chose 
the full-length GP1,2 recombinant protein, GP1,2 mucin domain deleted glycoprotein and sGP 
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as the target proteins for selection to obtain aptamers that could target both the surface exposed 
GP1,2 and the intracellular mucin domain deleted GP1,2. Three SELEX experiments were 
performed 1280 (GP1,2Δmucin), 1281 (full-length GP1,2) and 1282 (sGP). Each SELEX 
experiment was performed using an oligonucleotide pool with a 53-nucleotide random region.  
Three separate pools were used and at different time intervals. Enrichment of unique clusters 
was evident in all three SELEX experiments when the frequency plots of initial round pool and 
final round pool was compared. A sequence comparison of the results of the three SELEX 
experiments revealed identical sequences in all three. Most of the sequences in SELEX 1281 
(Chapter 3) and SELEX 1282 (Chapter 2) were identical. Oligonucleotide (4797) was found 
in all three selections but bound none of the targets. Thus, oligonucleotide 4797 is likely to 
bind the background matrix that was common to all three SELEX experiments. One reason for 
the appearance of identical sequences in 1281 and 1282 was the similar tertiary structures of 
full length GP1,2 and sGP.   
The observation of the same sequences appearing in two SELEX experiments was 
unexpected and led to the question of the probability that same sequence could appear in two 
separate DNA pools in the absence of evolution of the sequences driven by selection. The 
probability of having oligonucleotides with identical sequences in separate pools is very low.  
The frequency plots of the RNA pools were 99% unique, which eliminates the hypothesis that 
sequences of oligonucleotides in the starting pools were redundant due to bias in the synthesis 
step. Another source of bias could be in the sequencing step. The complexity of the pool is 
1015 oligonucleotides representing a subset of the possible 1031 sequences and the NGS results 
average a million reads per pool. Other points of bias that could increase the representation of 
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certain sequences are the transcription and PCR steps. However, none of these sources of bias 
provide a credible explanation for the fact that many of the same sequences were isolated in 
two independently run SELEX experiments, which started with different RNA pools. The 
results could be explained by the combination of selection against target and the variations in 
sequence imposed by low fidelity amplification protocol.  If this is the explanation, it also 
suggests that the initial selections (round 1 and 2) are very efficient in capturing 
oligonucleotides with some affinity for the target. The remaining rounds of SELEX may be 
dominated by the evolution of sequences due to errors in replication and transcription, which 
expands the oligonucleotide populations that bind with high affinity. These results also suggest 
that the selected aptamers are either unique or amongst very few possible oligonucleotides that 
are capable of binding sGP with high affinity. 
Chapter 2 discusses the selection of high affinity 2’F RNA aptamers that bind to sGP 
with high affinity and specificity. MEME software was used to search for sequence structure 
motifs in the oligonucleotides for which sequences were found in the SELEX 1281 and 
SELEX1282 top clusters. We identified polyU rich sequences in the selected oligonucleotides 
from both SELEX experiments. Poly U rich sequences are known to bind intracellular 
regulatory RNA binding proteins [6]. We found that the oligonucleotides 5177, 5182, 5183 
and 5179 with poly U rich sequences bound sGP with high affinity, whereas oligonucleotides 
4789 and 5181 lacking poly U rich sequences bound with low affinity. We tested the 
dependency on 2’FY modification for high affinity binding and found that unmodified 2’OH, 
5183 RNA did not bind sGP. From this result, we concluded that binding of oligonucleotide 
5183 to sGP depends on the 2’fluoro modification of the pyrimidines. This observation is 
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consistent with earlier reports of enhanced affinity of RNA aptamers to target proteins due to 
2’F modification [7].  
To identify the aptamer sequence in the larger 5183 oligonucleotide, oligonucleotides 
with sequences that were truncations of the parent 5183 sequence were tested for binding to 
sGP. These results confirmed the central role of the polyU-rich loop in binding sGP as the 
truncated 39mer containing the hairpin U loop sequence bound sGP most effectively. This 
39mer was demonstrated to bind sGP with high affinity and was given the aptamer name 
39SGP1A. Our long-term goal is to integrate the selected aptamer on a detection platform. 
Therefore, we tested the affinities of this aptamer for the serum proteins, human serum 
albumin, fibrinogen and α2-macroglobulin.  
It is important for the application of 39SGP1A to diagnostics that it not bind to other 
proteins in the blood. The parent proto-aptamer, 5183 binds sGP with a Kd of 400 nM 
compared with a Kd of 40 nM for sGP. The concentration of human serum albumin (HSA) in 
blood is 300 μM, which means that the 5183 oligonucleotide would be saturated with HSA if 
incubated with a sample of serum. However, once the sGP binding element was isolated to the 
poly U stem and 5183 truncated to create the aptamer 39SGP1A there was no remaining 
affinity for HSA.  
In chapter 3, for selections against GP1,2 in SELEX 1280 and 1281 no conserved 
sequence structural motif was found. Therefore, the affinity of oligonucleotides with sequences 
in the SELEX 1280 selected families and unique sequences from SELEX 1281 were tested for 
binding to GP1,2 with and without the mucin domain attached.  From these tests, 
oligonucleotide 4789 was found to bind GP1,2Δmucin with high affinity whereas it did not 
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bind the full length GP1,2 glycoprotein. This oligonucleotide also bound sGP (Chapter1). 
Therefore, oligonucleotide 4789 appears to bind a domain that is common between sGP and 
GP1,2Δmucin, which is in the N terminal portion of the GP1,2 protein sequence. The N 
terminal region of GP1,2 and sGP is the conserved receptor binding domain suggesting that 
4789 binds the receptor binding domain of the glycoprotein. This aptamer might have the 
capability of intercepting viral host interactions. Tests of other oligonucleotides selected in 
SELEX 1281for binding to the full length GP1,2 (including the mucin domain) identified two 
sequences 5185 and 5187 that bound the full length GP1,2 and virus particles pseudotyped 
with the full length GP1,2. 
My thesis describes the development and characterization of sGP and GP1,2 specific 
2’FY-modified RNA aptamers. Additional studies are needed to determine if the aptamers 
selected against GP1,2 might provide therapeutic options. First, the specificity of these 2’FY-
RNA aptamers must be determined by testing their ability to bind other proteins and to bind 
GP1,2 in the presence of blood proteins. The selected aptamers to full length GP1,2 could 
target extracellular virus and the aptamers that recognize GP1,2 lacking the mucin domain 
might target the cleaved GP1,2 protein in the endosome. Because Ebola viruses have GP1,2 
independent mechanisms for entry, full length GP1,2 and GP1,2Δmucin aptamer chimeras 
could be effective. The GP1,2 RNA aptamer when bound with full length GP1,2 glycoprotein 
can facilitate the entry of both aptamers into the endosomes where the second aptamer to 
GP1,2Δmucin could thwart viral entry into the cytoplasm. The challenge at this step could be 
if these aptamers are unable to survive low pH endosomal conditions, which has not yet been 
tested. An alternative approach could be to conjugate these aptamers to known therapeutic 
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drugs for intervention of viral entry. An aptamer that neutralizes EBOV will provide a means 
for rapid, albeit transient, protection as a stop-gap measure prior to further treatment including 
isolation of the infected individual from others who might be susceptible. 
Our future goal for the selected aptamer 39SGP1A is to use it to detect sGP. The 
aptamer will be integrated onto microcantilever a platform that is equipped with a system to 
detect RNA aptamer-sGP interaction with high sensitivity and specificity such as was 
previously demonstrated with mouse lipocalin-2 [8] . Although, we have tested the aptamers 
for its specificity against human serum albumin, there are many known proteins present at 
various concentrations in the serum. Therefore, binding of these aptamers to sGP in the 
presence of serum should be evaluated. Aptamer efficiency is also determined by its tertiary 
folding, therefore following the integration of the selected aptamer onto a platform, it must be 
ensured that folding of the aptamer hasn’t been compromised.  
In summary, the work presented in this thesis focuses on the selection and 
characterization of 2’FY-RNA aptamers against Ebola viral glycoproteins. Results from the 
selections reveal various important factors responsible for the selection of high affinity 
aptamers. These include considerations with respect to designing the pool, ensuring evolution 
of oligonucleotide sequences and the importance of the 2’F modification in mediating high 
affinity interactions with proteins. These studies resulted in the identification of aptamers that 
bind sGP and GP1,2, which can be developed as antivirals or for detection of Ebola virus. 
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